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Bronchoalveolar lavage (BAL) Cellular Analyses as a Diagnostic Intervention for 
Patients Suspected with ILD in conjunction with HRCT Imaging 
 
Background 
Bronchoalveolar lavage (BAL) has gained acceptance to diagnose interstitial lung disease 
(ILD). Advent of high resolution computed tomography (HCRT) reduced the clinical utility 
of BAL. The present work utilized the recommendations of American thoracic society (ATS) 
to optimize BAL procedure and associated the finding with clinical examination and HRCT 
to precisely narrow down the cause for ILD.  
Method 
BAL was performed on ILD suspects at target site chosen based on HRCT.  The procedure, 
transport, processing and analysis of BAL fluid were performed as per ATS guidelines. The 
clinical data, HRCT findings and BAL report were used to narrow the diagnosis of ILD. Two 
tailed student T test was used to assess the significance. 
Result 
We were able to optimize the BAL procedure as per the recommendations of ATS. In the 
cohort of 50 patients, Idiopathic pulmonary fibrosis (8), hypersensitivity pneumonitis (17), 
connective tissue disorder (9), sarcoidosis (3), pneumoconiosis (5), ARDS (2), eosinophilic 
lung disease (2) and lymphangitic carcinomatosa (2), aspiration bronchiolitis (1) and 
pulmonary histocytosis (1) were diagnosed. Statistically significant variation in differential 
counts was found in different ILDs. We were able to classify different ILDs based on the 
criteria described by ATS. 
Clinical significance 
BAL along with clinical and HRCT findings improved the diagnostic accuracy by 
incorporating the disease diagnosis, acute or chronic nature of the disease and cause for acute 
exacerbation, which helped in better management of ILDs. 
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INTRODUCTION 
 Bilateral infiltrative diseases involving the lung parenchyma 
with a varying degree of inflammation and fibrosis, that may present 
acutely or more commonly as a chronic condition, are as a group named 
as Interstitial Lung Diseases(ILD). ILDs occur in immunocompetent 
individuals who do not have a clinical suspicion of infection or neoplasm. 
ILDs in general are characterised clinically by exertional dyspnoea, 
radiologically by bilateral pulmonary infiltrates, abnormalities in lung 
function and gas exchange. Pathological features are excessive collagen 
deposition along with fibroblastic proliferation, in interstitium, and also 
in the lumen of the smaller airways. 
 Chronic ILDs develops over a long duration and comprises of 
condition with known causes and idiopathic causes. ILDs due to collagen 
vascular diseases, and work related diseases like pneumoconioses, 
namely silicosis, asbestosis and coal workers pneumoconiosis and 
hypersensitivity pneumonitis are diseases with known causes. Interstitial 
lung diseases without a known cause are a group of disorders named as 
Idiopathic interstitial pneumonias, and a granulomatous lung disease 
called Sarcoidosis. Tables 1 and 2 show the clinical and histopathological 
classification of the ILDs respectively. 
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Table (1)1 
Collagen vascular diseases 
 
Scleroderma, polymyositis-
dermatomyositis, systemic lupus 
erythematosus,rheumatoid arthritis, 
mixed connective tissue 
disease,Ankylosing spondylitis 
Iatrogenic Antibiotics (notroflurantoin, 
sulfasalazine), antiarrhythmics 
(amiodarone, tocainide, 
propranolol), anti-
inflammatories(gold, 
penicillamine), 
anticonvulsants(dilantin), 
chemotherapeutic agents 
(mitomycin c,bleomycin, busulfan, 
cyclophosphamide, chlorambucil, 
methotrexate, azathioprine, BCNU 
[carmustine], procarbazine), 
therapeutic radiation, oxygen 
toxicity, narcotics 
Primary (unclassified) diseases Sarcoidosis, primary pulmonary 
Langerhans cell, histiocytosis 
(eosinophilic granuloma), 
amyloidosis, pulmonary vasculitis, 
lipoid pneumonia, lymphangitic 
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carcinomatosis, bronchoalveolar 
carcinoma, pulmonary lymphoma, 
Gaucher’s disease, Niemann-Pick 
disease, Hermansky-Pudlak 
syndrome, neurofibromatosis, 
lymphangioleiomyomatosis, 
tuberous sclerosis, acute 
respiratory distress syndrome 
(ARDS), AIDS, bone marrow 
transplantation, postinfectious, 
eosinophilic pneumonia, alveolar 
proteinosis, diffuse alveolar 
hemorrhage syndromes, alveolar 
microlithiasis, metastatic 
calcification 
Occupational / environment related Inorganic: silicosis, asbestosis, 
hard-metal pneumoconiosis, coal 
worker’s pneumoconiosis, 
berylliosis, talc pneumoconiosis, 
siderosis (arc welder), 
stannosis(tin), 
organic(hypersensitivity 
pneumonitis), bird breeder’s lung, 
farmer’s lung  
Idiopathic fibrotic disorders Acute interstitial 
pneumonitis(Hamman Rich 
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syndrome), idiopathic pulmonary 
fibrosis/ usual interstitial 
pneumonia, familial pulmonary 
fibrosis, respiratory bronchiolitis/ 
desquamative interstitial 
pneumonitis, cryptogenic 
organizing pneumonia, non specific 
interstitial pneumonia, lymphocytic 
interstitial pneumonia(Sjogren’s 
syndrome, connective tissue 
disease, AIDS, Hashimoto’s 
thyroiditis), autoimmune 
pulmonary fibrosis(inflammatory 
bowel disease, primary biliary 
cirrhosis, idiopathic 
thrombocytopenic purpura, 
autoimmune hemolytic anemia) 
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Table2(2) 
Histologic patterns Clinical Associations 
Usual interstitial pneumonia 
IPF: connective tissue 
diseases(uncommon ); asbestosis; 
hypersensitivity pneumonitis; 
chronic aspiration pneumonia; 
chronic radiation pneumonitis; 
Hermansky-Pudlak syndrome; 
neurofibromatosis 
Nonspecific interstitial pneumonia 
Idiopathic; connective tissue 
diseases; drugs; hypersensitivity 
pneumonitis; diffuse alveolar 
damage; infections; lymphocytic 
interstitial pneumonia; AIDS; 
chronic eosinophilic pneumonia; 
infections; hemosiderosis; alveolar 
proteinosis 
Diffuse alveolar damage 
Acute interstitial 
pneumonia(Hamman-Rich 
syndrome); acute respiratory 
distress syndrome; drugs(cytotoxic 
agents, heroin, cocaine, paraquat, 
ethchlorvynol, aspirin); toxic gas 
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inhalation; radiation therapy; 
oxygen toxicity; connective tissue 
disease; infections(Legionella, 
Mycoplasma, viral) 
Organizing pneumonia  
Cryptogenic organizing pneumonia; 
organizing stage of diffuse alveolar 
damage; hypersensitivity 
pneumonitis; eosinophilic 
pneumonia; Wegener’s 
granulomatosis 
Desquamative interstitial 
pneumonia/ respiratory 
bronchiolitis 
Cigarette smoking; idiopathic; 
connective tissue diseases; primary 
pulmonary Langerhans cell 
histiocytosis; asbestosis; hard-metal 
pneumoconiosis(cobalt); Gaucher’s 
disease; Niemann-Pick disease; 
Hermansky-Pudlak syndrome; 
drugs(nitrofurantoin, amiodarone) 
Lymphocytic interstitial pneumonia 
Idiopathic; 
hypogammaglobulinemia; 
autoimmune disease, including 
Hashimoto’s thyroiditis, lupus 
erythematosus, primary biliary 
cirrhosis, Sjogren’s syndrome, 
myasthenia gravis, chronic active 
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hepatitis; AIDS; allogeneic bone 
marrow transplantation. 
Eosinophilic pneumonia 
Idiopathic acute and chronic; 
tropical filarial eosinophilia; 
parasitic infections; allergic 
bronchopulmonary aspergillosis; 
allergic granulomatosis of Churg 
and Strauss; hypereosinophilic 
syndrome; AIDS. 
Alveolar proteinosis 
Pulmonary alveolar proteinosis; 
acute silicosis; aluminium dust; 
AIDS; myeloproliferative disorder 
Diffuse alveolar hemorrhage with 
capillaritis 
Wegener’s granulomatosis; 
microscopic polyangiitis; systemic 
lupus erythematosus; polymyositis 
scleroderma; rheumatoid arthritis; 
mixed connective tissue disease; 
lung transplantation; drugs( retinoic 
acid, propylthiouracil, dilantin); 
Behcet’s disease; 
cryoglobulinemia; Henoch-
Schonlein purpura; pauci-immune 
glomerulonephritis; immune 
complex glomerulonephritis. 
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Diffuse alveolar hemorrhage 
without capillaritis 
Idiopathic pulmonary 
hemosiderosis; systemic lupus 
erythematosus; Good pasture’s 
syndrome; diffuse alceolar damage; 
pulmonary veno-occulsive disease; 
mitral stenosis; 
lymphangioleiomyomatosis. 
Amyloid deposition 
Primary amyloidosis; multiple 
myeloma; lymphocytic interstitial 
pneumonia. 
Granuloma  
Sarcoidosis; hypersensitivity 
pneumonitis; pulmonary 
Langerhans cell histiocytosis; 
silicosis; intravenous talcosis; 
berylliosis; lymphocytic interstitial 
pneumonia; infections. 
 
Though the causes of ILDs are daunting, the various ILDs have 
similar characteristics: clinical features, physiologic abnormalities, 
imaging patterns and histologic patterns. Nevertheless,in many patients, 
specific diagnosis can be made from clinical history,laboratory tests , 
HRCT features. Bronchoalveolar lavage(BAL) done by fiberoptic 
bronchoscope and in some cases transbronchial biopsy of yield a 
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diagnosis of some ILDs. Surgical Lung Biopsy(SLB) either through a 
Video assisted thoracoscopic surgery(VATS) or by open thoracotomy 
maybe required in the remaining cases.  
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A BRIEF LOOK INTO THE CLINICORADIOLOGICAL, 
PHYSIOLOGICAL CHARACTERISTICS OF ILDS 
The three major hallmarks of ILDs are progressive dyspnoea, 
characteristic imaging abnormalities, and abnormal lung function tests.2 
But, some patients may have a normal Xray chest at the time of clinical 
presentation. All the three features need not be present at the time a 
patient seeks medical attention. A dyspnoeic patient may have a normal 
spirometry, or a patient with radiologic findings maybe asymptomatic at 
the time of diagnosis. HRCT of the chest and exercise testing unmasks 
abnormalities in these patients. BAL can detect abnormalities even when 
a patient has normal xray or lung function tests, by revealing 
inflammatory cells,in conditions with high risk of developing ILD like 
those with CTD, asbestos exposure ,intake of drugs known to cause ILDs 
or hypersensitivity pneumonitis.   
A thorough history is very important. Occupational history should 
be elaborate as an exposure several years ago can be the cause of the 
disease in certain conditions. The exposure could have been for a short 
duration, but of high intensity. Hyperensitivity pneumonitis must be 
excluded, and it may present as an insidious or as a recurrent acute or sub 
acute pneumonitis.  
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DRUG AND TOBACCO HISTORY: 
Drug history should include a review of medications used recently 
as well as in the distant past. Aspiration of gastric contents can lead to 
ILD. History of tobacco use is important, some ILDs are more 
predominant in smokers like Pulmonary Langerhans Cell 
histiocytosis(PLCH), Respiratory bronchiolitis. Smoking also has 
prognostic value in certain conditions, almost all patients with 
Goodpastures syndrome have diffuse alveolar hemorrhage,while only one 
fifth of non smoking patients with Goodpasture’s syndrome have alveolar 
hemorrhage. Also smokers tend not to develop Hypersensitivity 
pneumonitis(HP) and Sarcoidosis, but in those smokers who develop HP, 
the disease runs a chronic course. IPF incidence is higher in smokers. 
FAMILY HISTORY: 
 Familial associations are seen in Sarcoidosis, IPF, tuberous 
sclerosis, Nieman –Picks disease, Gauchers, Hermnsky-pudlak 
syndromes. 
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GENDER: 
ILDs showing sex predilection are Lymphangioleiomyomatos  
(LAM) which occurs excusively in women, and CTD associated ILDs are 
more common in women; whereas Pneumoconioses and occupational 
ILDs are more likely in men.  
SYMPTOMS: 
Progressive dyspnoea is the most common symptom. Cough is 
prominent in Lymphangitic carcinomatosis (LC) and also in Sarcoidosis, 
cryptogenic organizing pneumonia(COP), Hypersensitivity Pneumonitis, 
PLCH and Respiratory bronchiolitis. Whezing is associated with CEP. 
Substernal chest pain can be a symptom in Sarcoidosis. Pleurisy type of 
pain may occur in drug induced ILDs,CTD-ILDs. Chest pain due to 
pneumothorax could be a presenting feature of PLCH, tuberous sclerosis, 
LAM, neurofibromatosis. Hemoptysis is occurs in Diffuse Alveolar 
Hemorrhage syndromes, and LAM. Hemoptysis in a case of known ILD 
should raise the possibility of a malignancy complicating ILD.  
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PHYSICAL FINDINGS: 
Bibasilar inspiratory crackles is the most typical auscultatory 
finding,though they are less likely in granulomatous conditions, followed 
by digital Clubbing. Clubbing is usually indicative of advanced fibrosis. 
As the disease progresses, signs of pulmonary hypertension and cor 
pumonale appear.  
PHYSIOLOGIC ALTERATIONS: 
Increased elastance, decreased compliance and impaired gas 
exchange manifest as hypoxia in ABG and a reduced diffusing capacity 
for carbon monoxide. Assessment of exercise tolerance is the most 
important physiologic determination in ILD patients and also correlates 
with disease severity.  
HRCT: 
With the advent of HRCT the need for invasive diagnostic 
procedures has reduced. HRCT identifies specific imaging patterns that 
can strongly support the diagnosis of certain ILDs or can be virtually 
diagnostic of some.HRCT alone can be diagnostic in the following 
conditions in the presence of features characteristic to them  
 Sarcoidosis 
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 Idiopathic Pulmonary Fibrosis  
 Subacute Hypersensitivity Pneumonitis 
 Lymphangitis carcinomatosis 
 LCH 
  LAM 
 Pulmonary alveolar proteinosis (PAP) 
HRCT has greatly improved the clinicians ability to shortlist the 
differential diagnosis, and could be diagnostic in many conditions(1-3)  
GALLIUM SCAN: 
It is a non invasive test for staging sarcoidosis but is not 
recommended for IPF, as interpretation is difficult. Its non specific and 
the scan could be negative in the presence of the disease. 
VENTILATION-PERFUSION LUNG SCANNING: 
In IPF it shows non segmental inhomogeneities, scattered regions of 
varying VP match. 
ROLE OF MRI : 
MRI maybe helpful in differentiation of fibrotic lesion from 
inflammation. 
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EXERCISE: 
A very important functional parameter in Interstitial lung disease is 
gas exchange assessment during exercise since it could be normal when 
the patient is resting. 
BRONCHOALVEOLAR LAVAGE: 
Bronchoalveolar lavage is done through a fiberoptic bronchoscope 
which is wedged into a selected bronchopulmonary segment, through 
which saline is instilled and retrieved. It is done to sample the distal 
airways. The retrieved sample represents the cellular, immunologic and 
biochemical mileu. 
Methods to analyse the sample and performing the procedure has 
been setforth by a multicenter publication3. BAL could be diagnostic in 
bronchoalveolar carcinoma; pulmonary lymphoma and lymphangitis 
carcinomatosa. BAL is therapeutic in pulmonary alveolar proteinosis. 
BAL could be diagnostic of Langerhans cell histiocytosis if histocytes are 
in excess of 5%. Populations at risk of ILD, like those with connective 
tissue disease can be assessed with BAL cellular profile, even in the 
absence of clinical or radiological evidence of ILD. In such patients BAL 
reveals increases in inflammatory cell populations. 
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HISTOLOGICAL DIAGNOSIS: 
In the evaluation of an ILD patient, the decision to go for tissue 
diagnosis is the last step. A thorough history taking leads to a diagnosis in 
patients with CTD, occupational ILD and drug induced ILDs. But in the 
case of IIPs, only a suggestive diagnosis may be obtained from 
clinicoradiological and laboratory findings. And in many a situation, a 
diagnosis of IPF may only be established by histological findings of usual 
interstitial pneumonia pattern. When transbronchial biopsy does not 
yield,the next step is a Surgical lung biopsy. The utility of BAL cell 
analyses is a subject of difference in opinion as the findings are poor in 
sensitivity and specificity4 
The American Thoracic Society(ATS) issued guidelines to increase 
the yield of BAL in the diagnostic evaluation of ILD and in encourages 
its use in ILD suspects.  
This work utilizes the recommendations put forth by the ATS to 
optimize the BAL procedure and to associate the findings across different 
clinical entities of ILD including HRCT.  
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AIMS AND OBJECTIVES 
PRIMARY OBJECTIVE: 
To optimize the bronchoalveolar lavage(BAL) procedure as per the 
recommendations put forth by the American Thoracic Society for the 
cellular analysis of interstitial lung diseases. 
SECONDARY OBJECTIVES: 
Optimization of the BAL procedure as recommended by the 
American Thoracic Society. BAL cellular analyses association with 
clinical characteristics of different interstitial lung diseases and their 
radiological findings. 
 
 
 
 
 
 
 
 
 
 
 
18 
 
 
REVIEW OF LITERATURE 
The technique of bronchoalveolar lavage(BAL) was first described 
by Reynolds and Newball in 1974. Though BAL has some limitations, it 
is additive , if read in the clinical background. R.P.Baughman in his 
editorial “The uncertainties of bronchoalveolar lavage”has discussed 
about the retrieval of fluid during the bronchoalveolar lavage procedure 
and has concluded like this “ as one examines the lavage process closely, 
one can appreciate the uncertainty a physician may have about the 
retrieval process. The lavage process itself affects the results. Also, the 
lung is an active organ, secreting and absorbing protein and cells during 
the lavage procedure. I doubt that we will ever resolve the uncertainties 
of dilution that occur during lavage”. 
In 2010, Khilnani and Hadda in their editorial titled 
“Bronchoalveolar lavage: A forgotten tool!” have stated that "a minimally 
invasive tool for diagnosis which gives a vision into infectious, 
immunological and inflammatory processes" that occurs at the alveolar 
level. It is either diagnostic or helpful in revising the differential 
diagnosis. They have concluded the editorial like this “ although BAL has 
been used for more than 30 years, quite often this specialised technique is 
omitted because it is supposed to be a cumbersome procedure with 
limited diagnostic value. However, with experience it takes few 
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additional minutes to perform and the information gathered from it adds 
to the diagnostic value of FOB. Furthermore, therapeutic BAL where 
large amount of fluid is used to wash lower airway and is used for the 
treatment of pulmonary alveolar proteinosis. Therefore, it is suggested 
that every bronchoscopist should be well conversant with this not so 
commonly used technique.”  
THE NEED FOR A STANDARD PROCEDURE 
There are three populations of cells in the BAL.  
1. Cells sampled from alveoli. 
2. Cells in alveoli thats not lavaged.  
3. Cells from airways that contaminate the lavage sample  
Differences in BAL results were due to the differences in the 
technique of the BAL procedure practised in different parts of the world. 
Hence, ERS and ATS task force made recommendation for a standard 
procedure. 
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SAFETY AND SIDE EFFECTS OF BAL 
 The BAL procedure is relatively safe. Side effects if any are 
usually minor. They include cough and fever after the procedure, 
transient infiltrates in the chest X-Ray about 24 hours after the 
procedure, transient deterioration in FVC, FEVI, decreased oxygen 
tension. When a patient has an underlying disease with respiratory 
insufficiency supplemental oxygen is to be administered to 
maintain saturation at 92%. The safety of BAL is well established 
in adult respiratory distress syndrome(ARDS)6. ATS/ERS 
committee recommends the following regarding the BAL 
procedure 
 routine clinical and laboratory evaluation to diagnose bleeding 
tendencies  
 Site of BAL to be chosen based on HRCT findings, instead of a 
traditional BAL site  
 BAL procedure to be done, with the scope wedged into the selected 
segment 
  the unretrieved volume of instilled saline should not exceed 100ml  
 the suction pressure is maintained below 100mm Hg and visual 
collapse of the airway is avoided.  
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 if the total retrieved is less than 30% of the instilled saline 
volume,the differential cell count will be misleading to the 
clinician 
 if the fluid retrieved is less than 5%,the procedure is abandoned to 
prevent complications 
 20 ml of sample from the entire lavaged fluid is ideal for cell 
counts analyses  
BAL CELLULAR PROFILE IN VARIOUS ILDS AND THEIR 
CLINICAL APPLICATIONS: ATS CLINICAL PRACTISE 
GUIDELINES 
1. Idiopathic pulmonary fibrosis (IPF): IPF is a most frequently 
diagnosed Idiopathic interstitial pneumonia(IIP), hence,extensively 
studied. IPF is a distinct condition manifesting in the adult age 
group, and is characterised by usual interstitial pneumonia(UIP) 
pattern both pathologically and in high resolution CT scan of the 
chest. The lavage cellular differential in IPF characterised by 
predominant macrophages and modest elevation of neutrophils , 
eosinophils, but lymphocytes levels being normal. But, these 
features are not specific for ILD. Neutrophils counts range from 
5% to 30% in up to 90% of the patients with IPF. The neutrophils 
percentage may be proportional to the disease extent visualised by 
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imaging. Eosinophils counts about 5% are seen in up to 60% of the 
cases. Atypical features are eosinophils >20% or lymphocytes > 
15%. , suggest a diagnosis towards ELDs, COP, NSIP, HP, 
sarcoidosis,superadded infections. While BAL lymphocytosis 
implies response to steroid therapy, BAL neutrophilia is an 
independent predictor of mortality. The role of serial BAL to assess 
prognosis and response to treatment has not been established.  
AS A DIAGNOSTIC AID:  
 BAL cellular profile as a stand alone test cannot be a confirmatory 
test 
 Typical findings as mentioned above, along with UIP pattern in 
HRCT chest and supporting clinical criteria may provide a more 
confident diagnosis 
 BAL lymphocytosis >30% is against a diagnosis of IPF. 
Prognostic role: not established 
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2. NONSPECIFIC INTERSTITIAL PNEUMONIA (NSIP) 
It is a type of IIP with a better prognosis than IPF. NSIP is a 
pathological term used in lung biopsy specimens not suggestive of a clear 
pattern(7). It is further subdivided based on histopathology as cellular, 
fibrotic and mixed. Cellular NSIP has the longest survival rate, while 
fibrotic-mixed is the more common type Clinical presentation maybe of 
subacute or chronic onset. It is predominant in non smokers and in 
women.  
Lymphocytosis and decreased CD4/CD8 ratio are features of BAL 
profile in NSIP. Though not very specific, BAL cellular profile along 
with suggestive clinicoradiological findings can confirm a diagnosis of 
NSIP. However in fibrotic NSIP, BAL profile is similar to that of 
IPF/UIP. 
AS A DIAGNOSTIC AID: 
 Lymphocytosis with reduced CD4/CD8 ratio is seen in cellular 
NSIP.8 
 Lymphocytosis is not observed in fibrotic NSIP. 
 Diffuse ground glass opacities in HRCT along with BAL 
lymphocytosis support a diagnosis of cellular NSIP.  
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PROGNOSTIC VALUE:  
Unknown 
EOSINOPHILIC LUNG DISEASES(ELD) 
 ELD refers to a group of different disorders that have a 
characteristic accumulation of eosinophils as a common feature. With the 
inclusion of BAL in the diagnosis of ILD, the list of conditions grouped 
under ELD has expanded substantially,by detecting BAL eosinophilia in 
the absence of peripheral blood eosinophilia. Since ELD in acute 
presentation is often mistaken for severe pneumonia of acute origin, 
diagnosis is not promptly made9 . Chronic eosinophilic pneumonia(CEP) 
presents insidiously has a better prognosis. 
 Conditions that have BAL eosinophilia about 10% and below 
include chronic granulomatous disorders including tuberculosis and 
sarcoidosis, fungal diseases, IPF, collagen vascular diseases with lung 
involvement, pneumocystis carinii pneumonia.  
 Acute eosinophilic pneumonia clinically presents as an acute 
febrile illness, which can progress to respiratory failure and is often life 
threatening. BAL cellular profile shows a marked eosinophilia (>25%) 
and has a diagnostic value BAL procedure can be done safely in a 
critically ill patients in whom lung biopsy is not an option. The diagnosis 
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of AEP is strengthened when the lavage fluid characteristics are similar to 
that of diffuse alveolar damage10. Prompt diagnosis enables early 
treatment with systemic corticosteroids resulting in rapid and complete 
recovery Chronic eosinophilic pneumonia(CEP): occurs predominately in 
females11. BAL cellular eosinophilia is diagnostic and responds to 
corticosteroid therapy. BAL fluid analysis also averts the need for a 
surgical lung biopsy in these patients 
Allergic Bronchopulmonary Aspergillosis(ABPA): is characterised 
by wheezing, peripheral blood eosinophilia, and lung manifestations of 
bronchiectasis, a sequela of allergic/immune reaction to aspergillus 
colonising the airway lumen. ABPA affects previous asthmatics and 
cystic fibrosis patients. This condition is characterised radiologically by 
fleeting pulmonary opacities due to eosinophilic aggregation and or 
mucus plugging. CT findings and clinical features coupled with 
eosinophilia is characteristic of this condition. BAL fluid shows a high 
percentage of eosinophilia, which coupled with radiological findings 
strongly support the diagnosis. 
Sarcoidosis is a granulomatous disorder that can involve any organ. 
It most affects the lungs. Usually occurs in adults. Sarcoidosis is 
characterised by the presence of hilar adenopathy, lung infiltrations, eye 
and skin involvement. Due to its varied clinical manifestations and global 
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prevalence, sarcoidosis can simulate other inflammatory/infectious 
disorders. Commonly affected organs are the lungs, the lymphatic system, 
eyes, skin, hepatic, skeletal, cardiovascular and neurological systems. 
ATS criteria to diagnose lung sarcoidosis are 
i. suggestive clinical features and radiology findings 
ii. documenting of non caseating granulomas on biopsy 
iii. exclusion of other causes granulomatous inflammation 
The sarcoid granulomas have a rim of lymphocytes in their 
periphery and BAL enables the airspace. Lymphocytes recovery 
and these are mostly activated T-cells belonging to Th-1-
phenotype. Hence, in 1999, ATS/ERS statement included 
“heightened Th-1 immune response” instead of CD4/CD8 ratio12 
T-cell prominence in granulomatous tissues leads to a reduction in 
peripheral blood lymphocytes. 
BAL has contributed immensely in understanding the immunology 
and pathogenesis of sarcoidosis. Studies have demonstrated a 
significant correlation between bal cellular profile and lung biopsy 
specimens13-15. The BAL lymphocytosis correlates with activity of 
the disease, but a normal lymphocyte percentage can also be seen 
in the minority of patients. Increased neutrophils are seen in 
advanced sarcoidosis. Other BAL parameters in sarcoidosis include 
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neutrophils and eosinophils and a lack of foamy alveolar 
macrophages. 
The diagnostic value of CD4/CD8 ratio has been debated as it 
shows a high variability in sarcoidosis14,15, and in a significant proportion 
of patients this ratio might be decreased. Though CD4/CD8 ratio might 
be low in sensitivity, it has a specificity of 95% (16-18). 
The diagnostic value of BAL lymphocytosis is strengthened if 
CD4/CD8 ratio is also higher 19 
ATS committee concludes that BAL fluid shows an increased 
lymphocytes but BAL lymphocytosis is not always present. A high 
CD4/CD8 ratio strongly supports the diagnosis. 
A high CD4/CD8 ratio along with BAL lymphocytosis, coupled 
with clinical and radiological findings suggestive of sarcoidosis strongly 
support the diagnosis. Neither lymphocytosis nor CD4/CD8 has any 
prognostic value. 
Hypersensitivity pneumonitis (HP) constitutes lung diseases 
characterised by a granulomatous lung disease that involves airways, 
alveoli and interstitium due to repeated inhalation of organic and 
chemical antigens, and sensitisation. 
HP is typically characterised by alveolitis with lymphocytes 
accumulation and granulomatous inflammation. 
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By clinical presentation, it is classified into acute, subacute and 
chronic forms. Chronic forms have a variable longterm outcome but often 
leads an irreversible parenchymal damage. The clinical presentation 
depends on the nature of the antigen, the amount of exposure, duration of 
exposure response of Host. HP affects non smokers preferentially20-23. 
The apparent protective effect of smoking is thought to be due to local 
immune suppressive effects24,25. But, smoking does not seem to have a 
suppressive role once the disease has established 22. 
In smokers who develop HP, the disease tends to run a chronic 
course26,27. BAL findings in HP are influenced by the clinical 
presentation- acute or chronic, smoking habits and the inhaled antigen 
characteristics. 
BAL cellular profile in HP characteristically shows a marked 
lymphocytosis, often in excess of 50%, whereas lymphocyte percentage 
under 30% leads to an uncertainty in diagnosis. 
The ATS committee has made the following conclusions: 
1. With BAL lymphocytosis more than 50% along with clinical 
and radiological features consist with HP, a confident diagnosis 
can be made  
2. To suspect alternate diagnosis in the absence of BAL 
lymphocytosis 
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Prognostic value of BAL in HP is uncertain 
CVD/CTD 
Understanding of various pattern of diffuse parenchymal lung 
diseases that affects rheumatological patients has improved considerably 
in the recent times. Most of this progress from the time of publication of 
classification of IIP28. Diffuse lung disease occur in different patterns in 
rheumatological diseases. Sub clinical lunseases could be identified in 
asymptomatic patients diagnosed with a rheumatological diseases when 
routinely assessed for pulmonary pathology. The histopathological 
patterns of UIP, LIP, COP, NSIP, DIP and DAD are all seen in 
rheumatological patients, often coexisting with diseases of the airways 
such as broncholitis obliterans and  
ATS/ ERS task force published ‘clinical guidelines and indications 
for BAL’ in 1992 in which CTD cases were further divided into CTD 
with IID and CTD without IID. And the predominant abnormalities 
reported were an increase neutrophils in RA, Sjogrens and SLE. While 
SSC had increased neutrophils and eosinophils. And the document 
concluded that the diagnostic value was limited to differentiating an 
infection, drug induced disorder or hemorrhage. With more studies 
focussed on rheumatological disease, clearer messages are emerging. 
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SSC 
Bouros et al29 studied BAL cellular profile in 73 cases of systemic 
sclerosis observed elevated neutrophils with elevated eosinophils or 
elevated lymphocytes. Eosinophils elevation was observed in patient who 
had NSIP pattern, but not in those with UIP pattern. Lymphocytes 
elevation was observed in cellular NSIP pattern( on HPE). Furthermore, 
elevated neutrophils correlated with extensive lesions on HRCT while 
lymphocytes elevation was present irrespective of any abnormality in 
HRCT was present or not. Some studies have described that neutrophil 
excess is a marker of progressive disease30,31,32 while another studies 
states that neutrophils excess implies more explosive disease and not a 
progressive one33. Recently two large clinical trials failed to find any 
useful correlation of BAL cellular profile with either treatment response 
or progressive of the disease34,35 
The committee has concluded that the predominant profile in SSc 
is neutrophilia with or without eosinophilia and lymphocyte is associated 
with cellular-NSIP. BAL cellular patterns do not determine if treatment is 
required and do not help to monitor the activity of the disease. 
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RHEUMATOID ARTHRITIS 
In the study by J.G.Garcia et al with a sample size of 24, three 
groups were observed.  
1) Patients with clinical symptoms and radiological evidence of 
lung disease showing neutrophilia in BAL.  
2) Patients with only radiological evidence showing BAL 
lymphocytosis  
3) Third group without clinical and radiological evidence, have 
a normal BAL cell differential.  
These findings interpreted that symptomatic patients with 
lung lesions had lymphocytosis while diffuse lung disease 
had BAL neutrophilia. Based on several other studies the 
committee has concluded that lymphocytosis is a more 
characteristic feature in RA than in systemic sclerosis.  
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PRIMARY SJOGREN’S SYNDROME 
Based on a few studies in primary sjogren’s with lung 
involvement(36)-salaffi et al and Delavanga et al it has been observed that 
BAL lymphocytosis is associated with a good outcome while neutrophilia 
with persistent disease. To sum up conclusions of the ATS committee on 
clinical applications of BAL profile in all CTD/CVD- related ILDs: 
  Adequate studies of BAL in CVD is lacking 
 There is a paucity of studies correlating lavage findings with lung 
biopsy/HRCT findings 
 Lymphocytosis is a prominent finding in sjogren’s and RA. 
 Neutrophilic correlates with extent of pulmonary involvement in 
HRCT. 
 The clinical implication of an abnormal BAL cell differential is not 
known. 
Significance of lavaged cells differential in classification, and in 
managing of ILD in CTD are not known. 
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OCCUPATIONAL INTERSTITIAL LUNG DISEASE 
In a genetically susceptible person, occupational exposures can 
cause specific ILD’s. These exposures may have occurred several years 
ago Pneumoconiosis- caused by asbestos, silica and coal dust which get 
accumulated in the distal airways and lung parenchyma, which is met by 
a tissue reaction. Metal induced lung disorders that could be 
granulomatous or fibrotic, induced by beryllium, titanium, aluminum, 
iron, silver, etc. 
SILICOSIS: 
Crystalline silica exposure occurs in various occupational settings. 
Silicotic nodule is the histopathological hallmark of this condition and is 
formed by macrophages laden with dust and fibrosis tissue surrounding a 
hyalinised connective tissue. 
Eventually as disease progresses these nodules coalesce to produce 
large conglomerates that involve the pulmonary vessels, airways, and 
finally producing progressive massive fibrosis (PMF) 37-49 
Bronchoalveolar lavage profiles37-49 in workers exposed to silica as 
well as workers who had silicosis had an increase in macrophages which 
is significant in non-smokers. Lymphocytosis and neutrophilia seems to 
reflect the ongoing inflammatory process and progression to silicosis. 
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The committee has conclude that  
1) Lavage findings in workers with exposure and workers who 
had silicosis showed an increased macrophages even in non 
smoking individuals 
2) Lymphocytosis and neutrophilia in BAL are associated with 
progression to disease. 
PULMONARY LANGERHANS CELL HISTIOCYTOSIS  
It is a rare condition featuring an abnormal proliferation of 
langerhans cells. 
This disease can be localised or involve multiple systems which 
were called Hand-Schuller-Christian disease, histiocytosis X, and 
Letterer-Siwe disease based on the various presentations, is now called 
Langerhan Cell Histiocytosis(LCH) 51 
Pulmonary LCH(PLCH) has a variable clinical presentation. Most 
of the patients are smokers with non specific chest symptoms. One 
characteristic manifestation is recurrent pneumothorax. The pulmonary 
lesions consists nodules that take bronchiolocentric stellate shape. These 
contain Langerhans cells , eosinophils, plasma cells and lymphocytes. 
Eosinophils are found in active stages only. 
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BAL cellular profile is diagnostic in PLCH and obviates surgical 
lung biopsy52,53. Demonstrating langerhans cells in BAL fluid supports 
the diagnosis of PLCH in the presence of consistent clinical and 
radiological features54. Immunohistochemical studies or Birbeck granules 
demonstraton are highly specific for PLCH.  
By reviewing literature 55-58,59-64 it has been concluded by the 
committee that LC differential above 5% is highly supportive of PLCH 
diagnosis. But, low numbers of LC does not exclude PLCH. It has been 
observed that as disease progresses, LC percentage decreases.  
The committee concludes that  
 In the presence of clinical suspicion and suggestive HRCT 
findings, BAL cellular profile can help to confirm the diagnosis. 
 In the absence of the diagnostic HRCT findings, elevated CD1 a 
staining above 5% of cells is adequate for diagnosis 
 BAL finding of less than 5 percent CD1 cells do not exclude 
PLCH, who have clinical and radiological features consistent with 
a diagnosis of PLCH. 
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DRUG INDUCED LUNG DISEASE 
Drug induced ILD include a wide range of clinical presentations, 
mode of onset acute or chronic, lung pathologies and imaging patterns65,66 
which include Eosinophilic pneumonia, pulmonary fibrosis, HP, DAD, 
DAH, acute non cardiogenic pulmonary edema, and drug induced lupus. 
Most common patterns are  
1) An acute hypersensitivity response characterised by an 
elevated eosinophils levels in blood or in airspaces. 
 2) Subacute/Chronic response that may imitate certain forms of 
IIP and have fibrosis.  
Amiodarone related ILD is characterised by foamy 
macrophages67,68. Nitrofurantoin and methotrexate related ILD is 
characterised by elevated CD4 lymphocytes69,70 
Drug induced ILD in a patient with CTD/CVD is often difficult to 
establish as pulmonary toxicity may be superimposed on ILD that is 
already present. Nonetheless, HRCT often establishes a pattern that are 
consistent with specific drug exposures like pulmonary hemorrhage, 
pulmonary edema, fibrosis, ground glass attenuation. BAL eosinophilia 
or lymphocytosis suggest a favourable response to corticosteroid therapy. 
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CONCLUSIONS 
1. As a diagnostic aid: 
2. BAL cell profile along with HRCT characteristics could aid in 
diagnosing drug related ILD  
3. BAL is also useful to rule out pulmonary hemorrhage/ infections. 
RADIATION PNEUMONITIS 
Radiation fibrosis and radiation pneumonitis(RP) often complicate 
radiotherapy of malignancies. 
Radiation pneumonitis clinically manifests 1-3 months after 
radiation in about 8% of patients71,72. And radiation fibrosis takes about 6-
24 months to evolve and maybe observed in patients who did not suffer 
from radiation pneumonitis73 early pathological changes of small vessel 
injury, congestion and hyaline membrane formation may proceed to a 
chronic phase if the injury was severe, characterised by progressive septal 
thickening with vascular sclerosis74 
BAL lymphocytosis has been observed in the contralateral lung of 
patients who had radiotherapy for breast cancer75 which suggests the 
possibility that radiation pneumonitis may be an immune mediated 
response of the lung tissue to radiation by generating auto antigens. 
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Since patients undergoing radiotherapy have other possible causes 
for radiological infiltrates, BAL is often necessary to exclude 
hemorrhage, extension of malignancy, infections and drug toxicity. BAL 
cell profile in RP is characterised by elevated inflammatory cells. 
ATS Committee conclusions: 
 BAL is useful to exclude other causes of radiological infiltrates like 
hemorrhage/ infections 
 BAL lymphocytosis with consistent clinical and radiological findings 
supports the diagnosis of radiation pneumonitis. 
LYMPHANGITIC CARCINOMATOSIS 
BAL cellular analysis usually yield the diagnosis surgical biopsy 
often unnecessary pneumonitis. 
CHRONIC ASPIRATION PNEUMONITIS 
Lipid laden alveolar macrophages staining with oil-red O and a 
semiquantitative scoring method was described by some investigators to 
diagnose chronic recurrent aspiration. 
Identifying pepsin like activity might prove more useful in 
diagnosing gastric secretions aspiration. 
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ACUTE ONSET ILD 
 Marked elevation of eosinophils in BAL is diagnostic of acute EP. 
 BAL helps to diagnose infections and alveolar hemorrhage  
 marked elevation of lymphocytes in the background of consistent 
clinical settings suggests hypersensitivity pneumonitis or drug 
toxicity. 
HRCT IN THE DIAGNOSIS OF ILD 
HRCT of the chest has a high sensitivity of 94% for ILD whereas 
sensitivity of x-ray film is about 80%. HRCT can demonstrate early 
disease when the x-ray is apparently normal. But, HRCT does not always 
detect early disease demonstrated by histopathological examination. 
A study conducted by Vancouver group in 1989 was the first in 
establishing a role for CT in diagnosing ILD. They observed that x-ray 
chest as the first choice correctly diagnosed 77% while CT chest as the 
first choice diagnosed 93%. Grevier et al reported that by combining 
clinical, radiographic and HRCT findings the right diagnosis can be done 
in two thirds of patients. Certain diseases have very characteristic HRCT 
features obviating a need for biopsy 
ILDs which may exhibit very typical HRCT features are: 
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 IPF 
 Sarcoidosis 
 Subacute HP 
 LC 
 PLCH 
 LAM 
 Alveolar proteinosis. 
HRCT PATTERNS AND PROGNOSTIC SIGNIFICANCE: 
The ability of HRCT patterns in prediction of treatment response 
and outcome, etc has been extensively studied. 
The ground glass opacity pattern is predictive of a better response 
to treatment and longer survival than in patients with reticular pattern- in 
HRCT. 
Though at presence evidence is lacking to support HRCT routinely 
in monitoring the ILD patients, HRCT proves useful in explaining a 
sudden or unexpected clinical deterioration. HRCT is definitely superior 
to x-ray chest in diagnosing ILD and also in deciding upon an optimal 
site for biopsy when required. 
BAL/TBLB:In most of the ILDs, correct diagnosis can be made 
from putting together, clinical, laboratory and HRCT informations. 
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When HRCT features are typical of IPF,in addition to typical 
clinical features, surgical lung biopsy will not be necessary. BAL and/or 
TBLB could increase the diagnostic confidence in certain conditions like 
malignancy, infection, eosinophilia, HP-subacute, COP, sarcoidosis, rarer 
conditions like PLCH and PAP. 
The decision to perform BAL is informed by patient fitness, 
differential diagnosis, a supportive laboratory to do BAL cell differential 
count. 
BTS guidelines for TBLB in patients with ILD 
 TBLB when needed is to be performed prior to initiating specific 
therapy. 
 Bronchoalveolar lavage is to be considered in rare ILDs, suspected 
malignancy and infections. 
 With clinicoradiological features characteristic of IPF, BAL is 
necessary as a diagnostic intervention. 
 In the absence of typical clinical and radiological features, BAL 
cellular profile allows a confident diagnosis in sarcoidosis and 
hypersensitivity pneumonitis. 
 In the instance of diagnostic uncertainity where BAL is considered 
the important diagnostic tool, its preferably done in a center 
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specialised for the procedures and specialised in analysing the 
samples 
 BAL is to be done in all patients planned for TBLB 
 TBLB is the first line procedure in diseases with bronchocentric 
involvement 4-6 specimens must be taken. 
 TBLB is not reliable in rare lung disorders 
 
ILD AND THE UTILITY OF SURGICAL LUNG BIOPSY(SLB): 
BTS GUIDELINES 
 
SLB is the definitive note of establishing the diagnosis of IPF. SLB 
excludes infections and malignant processes which may occasionally 
mimic a chronic ILD. SLB can differentiate CHP from IPF, where CHP is 
a treatable disease. Disease activity can also be assessed by SLB. HPE 
diagnostic of IPF has a sensitivity above 60% and specificity almost 97%. 
Clinical radiological feature can diagnose IPF with a sensitivity and 
specificity of 48% and 89%. 
 
Studies that contain “changes in therapy” as a reported outcome, 
SLB contributed more. Hence SLB is ideally done in prior to 
immunomodulation therapy.  
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There are two approaches to obtain SLB. One is the traditional 
limit thoracotomy(OLB) and the other is through a video-assisted 
thoracoscopic approach(VATS). VATS is being increasingly used now a 
days. Both these procedures are performed under general anesthesia. 
Randomized controlled trials that compared open lung biopsy and VATS 
biopsy reported no significant differences in the time taken for the 
procedure, complications and diagnostic yield except for a reduced length 
of stay in hospital in the VATS group. 
 
SLB specimens ideally should be 4cm diameter with a depth of 3-
5cm from the pleural space. It should be promptly sent to the pathology 
laboratory, where it is inflated with formalin. Apart from HPE, PCR, in 
situ hybridization and immune histochemical techniques maybe applied 
to make most use of the biopsy specimen.  
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To summarise the recommendations for SLB in interstitial lung 
diseases. 
 SLB is to be done prior to initiating specific treatments. 
 SLB also provides a definitive diagnosis in IPF and other ILDs. 
 IPF can be diagnosed with confidence in the presence of typical 
clinicoradiological picture. 
 ILDs require multiple biopsy specimen from multiple lobes. 
 Multiple biopsy from differents lobes are easier to do with VATS 
 It has lesser early post operative pain compared to OLB. 
 Biopsy sites should be chosen based on HRCT findings. 
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MATERIALS AND METHODS: 
Proforma was designed and Institutional ethical committee 
clearance was obtained. 
The nature of the procedure and the purpose of the study was 
explained in detail to all the patients who were enrolled in this study and 
informed consent was obtained from all of them. Data was collected as 
mentioned in the proforma. 
SUBJECT SELECTION 
Fifty consecutive ILD patients were recruited based on clinical and 
radiological evaluation after institutional ethics committee approval. 
INCLUSION CRITERIA 
 ILD patients diagnosed based on clinical and HRCT findings. 
 Acute and chronic ILDs in immunocompetent patients 
 ILD patients tolerable to the procedure 
 Patients above the age of 18 years. 
  
EXCLUSION CRITERIA 
 ILD patients with bleeding disorders 
 ILD patients with cardiorespiratory instability 
 Pregnant women 
 Pediatric patients 
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SCREENING PROCEDURES 
Patients who were recruited were admitted in our hospital and were 
subjected to routine blood investigations including HIV testing, HRCT 
chest, cardiac and rheumatological evaluations. 
After obtaining cardiac fitness for the BAL procedure, patients whose 
respiratory status was adequate, were subjected to the BAL procedure. 
BAL PROCEDURE: 
 BAL was done using a flexible bronchoscope wedged into the 
chosen bronchopulmonary segment 
 The bronchopulmonary segment to be lavaged was selected based 
HRCT findings-areas with GGOs, profuse nodular lesions or thin 
reticulations were- optimal targets 
 Patients in whom the lavage site was other than the right middle 
lobe, positioning of the patient was adjusted retrieval. 
 The total volume of saline instilled was about 240ml, in aliquots of 
60ml. In all the patients, the retrieval volume was more than 
100ml. Four sequentially instilled aliquots were withdrawn 6 
 The first retrieval sample was sent for microbiological analysis 
 The samples were collected into a mucus extractor whose capacity 
was 25ml. about 4 to 5 such containers of sample was collected 
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from each patient and transported to the cytology laboratory in an 
ice box which maintains a temperature of 4oc. 
 Arrangements were made to analyse the sample for total cell 
counts, differential cell counts within one hour of the BAL 
procedure. 
 Throughout the BAL procedure, oxygen saturation of the patient 
was monitored and maintained above 92% 
 The suction pressure used during the procedure was under 
100mmHg, and was further adjusted to avoid visible airway 
collapse. 
 Before the sample was sent to the laboratory, gross appearance of 
the fluid was noted. 
 The BAL samples were pooled together in the laboratory and about 
20ml of the pooled sample was used for the cellular analysis. 
 
 
 
 
 
 
 
 
48 
 
 
TABLE 3:  
SUMMARY OF BAL CELLULAR PATTERNS IN 
NORMAL/HEALTHY ADULT NONSMOKERS AND IN 
PATIENTS WITH COMMON INTERSTITIAL LUNG 
DISEASES (CONSISTENT PATTERNS AND CLINICAL 
UTILITY) 
 
 
 
 
 
 
 
 
 
 
I. Normal Adults (Nonsmokers) BAL Differential Cell Counts 
Alveolar macrophages 85% 
Lymphocytes (CD41/CD81 ¼ 0.9–
2.5) 10–15% 
Neutrophils <3% 
Eosinophils <1% 
Squamous epithelial*/ciliated 
columnar epithelial cells† <5% 
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LYMPHOCYTIC 
CELLULAR PATTERN 
>15% LYMPHOCYTES 
EOSINOPHILIC 
CELLULAR PATTERN 
>1% EOSINOPHILS 
NEUTROPHILIC 
CELLULAR PATTERN 
>3% NEUTROPHILS 
Sarcoidosis Eosinophilic pneumonias Collagen vascular diseases 
Nonspecific interstitial 
pneumonia (NSIP) Drug-induced pneumonitis 
Idiopathic pulmonary 
fibrosis 
Hypersensitivity 
pneumonitis Bone marrow transplant Aspiration pneumonia 
Drug-induced pneumonitis Asthma, bronchitis Infection: bacterial, fungal 
Collagen vascular diseases Churg-Strauss syndrome Bronchitis 
Radiation pneumonitis 
Allergic 
bronchopulmonary 
aspergillosis Asbestosis 
Cryptogenic organizing 
pneumonia (COP) 
Bacterial, fungal, 
helminthic, Pneumocystis 
infection 
Acute respiratory distress 
syndrome (ARDS) 
Lymphoproliferative 
disorders Hodgkin’s disease 
Diffuse alveolar damage 
(DAD) 
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II. Interstitial lung diseases 
a. Disorders associated with increased percentage of specific BAL cell 
types 
b. Abnormal BAL differential cell patterns that suggest specific types 
of ILD 
A lymphocyte differential count >25% suggests granulomatous 
disease (sarcoidosis, hypersensitivity pneumonitis, or chronic 
beryllium disease), cellular nonspecific interstitial pneumonia, drug 
reaction, lymphoid interstitial pneumonia, cryptogenic organizing 
pneumonia, or lymphoma. 
 
CD4/CD8 is highly specific for sarcoidosis in the absence of an 
increased proportion of other inflammatory cell types. A 
lymphocyte differential count >50% suggests hypersensitivity 
pneumonitis or cellular nonspecific interstitial pneumonia. A 
neutrophil differential count >50% supports acute lung injury, 
aspiration pneumonia, or suppurative infection. 
 
 
51 
 
 
c. Other abnormal BAL findings 
 
Infectious organism 
Lower respiratory 
infection 
Malignant cells (light microscopy, flow 
cytometry) 
Cancer 
Bloody fluid that increases in successive aliquots 
Pulmonary 
hemorrhage 6 diffuse 
alveolar damage 
Milky fluid with positive periodic acid Schiff 
staining and amorphous debris 
Pulmonary alveolar 
proteinosis 
In vitro lymphocyte proliferative response to 
specific beryllium antigen 
Chronic beryllium 
disease 
Definition of abbreviation: BAL  
bronchoalveolar lavage. 
 
* The presence of squamous epithelial cells 
indicates upper airway secretion contamination. 
 
y Epithelial cells >5% suggest suboptimal sample 
(BAL cellular patterns should be interpreted with 
caution). 
 
52 
 
 
The above table was from ATS clinical practise guidelines is a 
reference used in this study and based on this we grouped Cellular 
patterns from the results obtained. “ The reason for routine cellular 
analysis whenever BAL is performed in a patient with suspected ILD is 
that identification or exclusion of the predominantly inflammatory 
cellular pattern may support a specific type of ILD or help narrow the 
differential diagnosis when considered in the context of the clinical and 
radiological findings. The notion that a prominence of specific nucleated 
inflammatory or immune cells in the BAL correlates with an increased 
likelihood of certain types of ILD is supported by numerous accuracy 
studies that are limited by risk of bias. These include pronounced BAL 
eosinophilia in eosinophilic pneumonia77,78, drug reactions79,81, BAL 
lymphocytes in sarcoidosis82-85, hypersensitivity pneumonitis86-88, 
pneumotoxic drug reactions89,90 or cellular NSIP91,92”. 
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Follow up procedures 
The patients who had undergone the procedure were observed for 
48 hours for post procedure bleed, followed up with chest x-rays 
immediately and 24 hours after the procedure. Those who did not require 
inpatient treatment were discharged with care. 
ASSESSMENTS OF PARAMETERS 
TECHNIQUE OF BAL CELL ANALYSIS 
 
The cellular analysis is performed within an hour from the time of 
procedure. The total cell count was done with a hemocytometer, and the 
viability of the cells was analysed by Trypan blue exclusion. The 
differential counting was done by cytocentrifugation after Wright-Giemsa 
staining and enumeration of at least 400 cells. The presence and relative 
numbers of erythrocytes and epithelial cells were noted. The presence of 
squamous epithelial cells suggests that BAL fluid is contaminated with 
upper airway secretions, and the presence of large numbers of bronchial 
epithelial cells suggests that the BAL may not have adequately sampled 
distal airspaces. Excess BAL fluid was stained and cultured for 
mycobacteria and fungi in the microbiology laboratory, as well as 
screened for neoplastic cells. These were important additional tests to 
consider because infections and diffuse neoplasms can masquerade as 
ILD or coexist with ILD. 
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INTERPRETATION OF BALL DIFFERENTIAL COUNTS 
The ranges of differential cell counts that are considered normal 
and abnormal derive from several sources. Numerous investigators have 
published BAL immune cell profiles from cohorts of clinically normal 
volunteer subjects recruited in single-center studies92-98 and these reports 
have been used to define normal and abnormal differential cell counts. In 
addition, the multi-center BAL Cooperative Study92 reported the 
differential cell counts in the BAL of normal subjects (including smokers 
or ex-smokers) compared with patients with ILD. An increased number 
of nucleated immune cells and abnormal proportions of immune cell 
types may suggest or support specific types of ILD in the absence of an 
infection. A mixed cellular pattern can be observed with any ILD; when 
mixed cellular patterns are observed, the dominant cell type may be the 
most consistent with a specific ILD diagnosis. A BAL fluid cell 
differential count with greater than 15% lymphocytes, greater than 3% 
neutrophils, greater than 1% eosinophils, or greater than 0.5% mast cells 
indicates BAL lymphocytosis (i.e., a lymphocytic cellular pattern), BAL 
neutrophilia (i.e., a neutrophilic cellular pattern), BAL eosinophilia (i.e., 
an eosinophilic cellular pattern), or BAL mastocytosis, respectively. A 
lymphocyte differential count greater than or equal to 25% suggests 
granulomatous lung disease (e.g., sarcoidosis, HP, NSIP, chronic 
beryllium disease, drug reaction, LIP, COP, or lymphoma), while a 
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lymphocyte differential count greater than 50% is particularly suggestive 
of HP or cellular NSIP. An eosinophil differential count greater than or 
equal to 25% is virtually diagnostic of eosinophilic lung disease in the 
appropriate clinical setting. A neutrophil differential count greater than or 
equal to 50% strongly supports acute lung injury, aspiration pneumonia, 
or suppurative infection. Finally, a mast cell differential count greater 
than 1% combined with a lymphocyte differential count greater than 50% 
and a neutrophil count greater than 3% is suggestive of HP. A 
predominance of macrophages containing smoking-related inclusions 
with no or minor increases in other cell types is compatible with 
smoking-related ILD, such as DIP, RBILD, or pulmonary Langerhans 
cell histiocytosis (PLCH). Additional tests to identify and count 
Langerhans cells in the appropriate clinical setting may be useful in 
narrowing the differential diagnosis. A predominance of hemosiderin-
laden macrophages is suggestive of chronic or occult alveolar 
hemorrhage syndromes resulting in pulmonary hemosiderosis or diffuse 
alveolar damage.  
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ATS Recommendations   “For patients with suspected ILD in 
whom BAL is performed, the lymphocyte subset analysis NOT be a 
routine component of BAL cellular analysis. The lymphocyte subset 
analysis (by cytometry or immunocytochemistry) will not be performed 
routinely, but rather would be performed if a lymphocytic disease is 
suspected or the initial BAL cellular findings identify a lymphocytosis. 
This suggestion is based upon the committee’s clinical experience that 
lymphocyte subset analysis is rarely helpful and potentially misleading in 
the absence of a clinically suspected lymphocytic disease or a 
lymphocytosis. Many investigators have characterized lymphocyte 
subsets on the basis of T helper (CD41) versus T suppressor (CD81) 
phenotypes, and have found correlations of the CD41/CD81 T 
lymphocyte ratio with specific disease processes such as sarcoidosis and 
hypersensitivity pneumonitis86,87,99,100. However, subsequent 
investigations have found that the CD41/CD81 ratio may not be 
significantly increased in a substantial number of patients with 
sarcoidosis101,102 or significantly decreased in a substantial proportion of 
patients with hypersensitivity pneumonitis103,104, and can change during 
the course of the disease process. In addition, the BAL CD41/CD81 T 
lymphocyte ratio varies with age and may be significantly increased in 
normal subjects105. These issues are discussed extensively in the portion 
of the online supplement that pertains to specific forms of ILD. However, 
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in the case of sarcoidosis, the combination of BAL lymphocytosis 
combined with a considerably increased BAL CD41/CD81 lymphocyte 
ratio (e.g., > 4) may increase the confidence of a diagnosis of sarcoidosis 
if other clinical features and imaging are consistent with this diagnosis, 
and lymphocyte subset determinations may be performed at the discretion 
of the pulmonologist if such analysis can be reliably performed in the 
clinical laboratory and is considered to be clinically useful. Finally, there 
are other tests that can be performed on BAL fluid on a case-by-case 
basis and may be helpful in specific clinical circumstances. Analysis by a 
cytopathologist is indicated if there are isolated cells that are suspicious 
for malignancy. Periodic Acid Schiff staining or Oil Red O staining may 
be helpful if pulmonary alveolar proteinosis or aspiration is suspected, 
respectively. Hemosiderin staining may be performed if hemorrhage is 
suspected and/or the initial BAL raises the suspicion of hemosiderin-
laden macrophages”. 
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STATISTICAL ANALYSIS: 
Non parametric analysis was performed on the cohort after finding 
the median values of different cell counts obtained from the fluid 
analysis. Overall significance of the cell counts between different ILD’s 
was assessed using SPSS version.13(SPSS, chicogo,IL) and P< 0.05 was 
considered significant.  
STUDY DESIGN: 
Prospective continuous study 
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RESULTS: 
Fifty consecutive ILD patients were recruited for the study after 
obtaining informed consent. Clinically suspected ILD patients were 
subjected to HRCT and based on HRCT findings, BAL was performed 
after selecting the site for fliud collection in the lungs, except for two 
patients with ARDS. The procedure, transport, processing and analysis of 
BAL fluid were performed as per ATS guidelines. The patients were 
segregated based on the ATS classification given in table 3.  
 
 
 
 
 
 
 
 
 
60 
 
 
TABLE 4 
DD1 
LYMPHOCYTIC 
CELLULAR 
PATTERN 
DD3 
EOSINOPHILIC 
CELLULAR 
PATTERN 
DD2 
NEUTROPHILIC 
CELLULAR 
PATTERN 
>15% lymphocytes >1% eosinophils >3% neutrophils 
sarcoidosis Eosinophilic 
pneumonias 
Collagen vascular 
diseases 
Nonspecific interstitial 
pneumonia(NSIP) 
Drug-induced 
pneumonitis 
Idiopathic pulmonary 
fibrosis 
Hypersensitivity 
pneumonitis 
Bone marrow 
transplant 
Aspiration pneumonia 
Drug-induced 
pneumonitis 
Asthma, bronchitis Infection: bacterial, 
fungal 
Collagen vascular 
diseases 
Churg-strauss 
syndrome Bronchitis  
Radiation pneumonitis 
Allergic 
bronchopulmonary 
aspergillosis 
Asbestosis  
Cryptogenic 
organizing 
pneumonia(COP) 
Bacterial, fungal, 
helminthic, 
pneumocystis infection 
Acute respiratory 
distress 
syndrome(ARDS) 
Lymphoproliferative 
disorders 
Hodgkin’s disease Diffuse alveolar 
damage(DAD) 
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OTHER ABNORMAL BAL FINDINGS 
DD4(lymphocyte 
differential 
count>=25%) 
DD5(lymphocy
te differential 
count>50%) 
DD6(neutrop
hil differential 
count>50%) 
DD7(eosinop
hil differential 
count>25%) 
DD8(cell 
differential 
count 
>1%mast 
cells 
Suggests 
granulomatous 
disease(sarcoidos
is, 
Hypersensitivity 
pneumonitis or 
chronic beryllium 
disease), cellular 
nonspecific 
interstitial 
pneumonia,drug 
reaction,lymphoi
d interstitial 
pneumonia, 
cryptogenic 
organizing 
pneumonia or 
lymphoma. 
CD4+/CD8+>4 is 
highly specific 
for sarcoidosis in 
the absence of an 
increased 
proportion of 
other 
inflammatory cell 
types. 
Suggests 
hypersensitivit
y pneumonitis 
or cellular 
nonspecific 
interstitial 
pneumonia. 
Supports 
acute lung 
injury, 
aspiration 
pneumonia or 
suppurative 
infection. 
Virtually 
diagnostic of 
acute or 
chronic 
eosinophilic 
pneumonia. 
>50% 
lymphocytes 
and > 3% 
neutrophils is 
suggestive of 
acute 
hypersensitivi
ty 
pneumonitis. 
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Infectious organism  Lower respiratory infection 
Malignant cells(light microscopy, 
flow cytometry) 
Cancer 
Bloody fluid that increases in 
successive aliquots 
Pulmonary hemorrhage, diffuse 
alveolar damage 
Milky fluid with positive periodic 
acid Schiff staining and amorphous 
debris 
Pulmonary alveolar proteinosis 
In vitro lymphocyte proliferative 
response to specific beryllium 
antigen 
Chronic beryllium disease 
 
The segregation of the cohort as per the clinical diagnosis is as 
follows: idiopathic pulmonary fibrosis(IPF-8), hypersentivity 
pneumonitis(CHP-17), connective tissue disorder(CVD-9), 
sarcoidosis(SAR-3), pneumoconiosis(SIL-5), ARDS(2), eosinophilic lung 
disease(ABPA-2) and lymphangitic carcinomatosa(LC-2), aspiration 
bronchiolitis(AB1) and pulmonary histocytosis(PLCH) The demographic 
data and the finding are listed in table 5. 
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S.NO ID# AGE/SEX S A EXP D.O.I PFT RHE BAL1 BAL2 
HRCT 
DD 
CLI+BA
L 
CLI+BA
L+HRCT
+OTHER
S 
1 IPF1 49/M _ _ O.D 2yrs Res _ DD1,DD2 
DD6,DD
4 
UIP-DD 
IPF,NSIP
,CHP 
IPF,NSIP
,ALI,S.A.
I 
IPF-
AE+SAI 
2 IPF2 56/M + _ _ 2yrs Res _ DD1,DD2 DD4 UIP-DD IPF IPF 
3 IPF3 52/M + _ _ 3`yrs Res _ DD1,DD2 
DD3,DD
4 UIP-DD 
IPF,BA,E
LD,INF 
IPF-AE 
BRONC
HITIS 
SAI 
4 IPF4 37/M _ _ _ Yrs Res _ DD1,DD2 DD4 UIP-DD IPF,CHP IPF 
5 IPF5 50/M + + _ 3yrs Res _ DD1,DD2,DD3 DD4 UIP-DD 
INF,IPF,
ELD,BA,
ABPA 
IPF-
AE+SAI 
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6 IPF6 54/M _ +  1yr Res _ DD1,DD2 _ UIP-DD IPF IPF 
7 IPF7 64/M + +  4yrs Res _ 
UPPER 
AIRWA
Y 
COMTA
MINATI
ON 
UIP IPF IPF 
8 IPF8 49/M + _  6months Res _ LCH LCH 
?CYSTI
C 
DISEAS
E?+IPF(p
lain CT) 
LCH LCH 
9 IPF9 50/M _ _ _ 4yrs Res _ DD1,DD2 _ 
IPF 
FIB-
NSIP 
INF 
IPF-AE 
SA.I 
IPF-AE 
SAI 
10 HP1 75/M _ + PEST 20yrs Res _ DD1,DD2 DD4 
CHP,NSI
P,SAR CHP,INF CHP,SAI 
11 HP2 55/M + + _ 10yrs Res _ DD1,DD2,DD3 DD4 
SIL,SAR,
CHP,NSI
P 
HP,SAR,
BA,INF,
NSIP 
HP,SAI 
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12 HP3 61/F _ _ COTTON 15yrs Res _ DD2 DD6 
SIL,SAR,
CHP,NSI
P,B’LIM
S 
AP,SI,A
RDS CHP,SAI 
13 HP4 55/M _ _ POULTRY 10yrs Res _ 
DD1,DD
2 DD4 
HP,SAR,
NSIP,AI
P 
IPF,SAR,
CHP CHP,SAI 
14 HP5 65/M + +  40yrs Res _ DD1,DD2 DD4 
HP,SAR,
SIL,NSIP
,IPF 
HP,SAR,
NSIP,BR
ONCHIT
IS 
CHP,SAI 
15 HP6 37/M _ +  18yrs Res _ DD1,DD2, DD4 
DD-
FIBROSI
S,DD-
CLN 
HP,SAR,
NSIP-
CEL 
HP-
Subacute 
16 HP7 58/M _ +  15yrs Res _ DD1,DD2 DD4 
DD-
FIBROSI
S 
HP,SAR,
IPF HP 
17 HP8 25/F _ _  14yrs Mxd _ DD1,DD2 DD5 
AHP,DD
-
GGO,DD
-CLN 
HP,AHP Acute HP 
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18 HP9 58/M _ _ PEST 40yrs Res _ DD1,DD2 DD4 
DD-
FIBROSI
S 
IPF,HP,N
SIP CHP 
19 HP10 58/F _ _  15yrs Res _ DD1,DD2 DD4 
DD-
FIBROSI
S 
HP,IPF,N
SIP,SAR,
SAI 
CHP,SAI 
20 HP11 26/M _ _  20days Mxd _ DD1,DD2 DD5 
DD-
GGO,DD
-
CLN,AH
P 
HP,NSIP,
SAR AHP 
21 HP12 58/M _ _ PEST 10yrs Res _ DD1,DD2 DD4 
DD-
FIBROSI
S 
HP,NSIP,
SAR,INF CHP 
22 HP13 73/M _ + PEST 20yrs Res _ DD1,DD2 DD4 CHP,IPF 
CHP,SA
R,IPF CHP 
23 HP14 48/M + _ _ 15yrs Res _ DD1,DD2 DD4 CHP,IPF 
CHP,SA
R,IPF,NS
IP 
CHP 
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24 HP15 55/M _ _ BIOMASS 5yrs Res _ 
DD1,DD
2  IPF,CHP 
IPF,CVD
,SAR,SIL CHP 
25 HP16 60/M _ + PEST 6yrs Res _ DD1,DD2 DD4 
DD-
FIBROSI
S 
HP,NSIP,
SAR CHP 
26 HP17 30/M _ + WELD 3yrs Res _ DD1,DD2 DD4 
DD-
FIBROSI
S 
HP,NSIP,
SAR CHP 
27 CVD1 45/F - - - 1YR RES RA DD1,DD2 DD5 
DD-
INTERL
OOBAR 
SEPTAL 
THICKE
NING+U
IP 
CVD,IPF
,NSIP,HP 
CVD-
ILD 
28 CVD2 61/F - - - 2YRS RES RA DD1,DD2 DD4 UIP,DD 
IPF,CVD
,BRONC
HITIS 
CVD-
RA-ILD 
29 CVD3 38/M - - - 2YRS RES RA DD1,DD2  DD-GGO 
IPF,CVD
,CHP,BR
ONCHIT
IS 
CVD-
RA-ILD 
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30 CVD4 52/F - - - 1YRS RES RA DD1,DD2 DD4 
DD-
GGO,NS
IP 
CVD,IPF
,BRONC
HITIS 
CVD-
RA-ILD 
31 CVD5 64/F - - - 1YRS RES RA DD1,DD2 DD4 DD-GGO IPF,CVD 
CVD-
RA-ILD 
32 CVD6 44/M + + - 3YRS RES RA DD1,DD2 DD4 DD-GGO 
IPF,CVD
,INF,BR
ONCHIT
IS 
CVD-
RA-ILD 
33 CVD7 22/F - - - 
ASYMP
TOMATI
C 
RES SSc DD,DD2  IPF/CVD IPF,CVD,NSIP, 
CVD-
SSc-ILD 
34 CVD8 26/F - - - 
ASYMP
TOMATI
C 
RES SScc DD2  DD-UIP IPF,CVD,INF 
CVD-
SSc-ILD 
35 CVD9 48/F - - - 1YR RES RA DD1,DD2  
DD-
GGO+H
ONEYC
OOMB 
IPF,CVD
,HP 
CVD-
RA-ILD 
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36 SAR1 25/F - - - 
NIL 
RESPIR
ATORY 
NORMA
L - 
DD1,DD
2 DD4 
TB,SIL,S
AR,LYM
PHOMA 
TB/SAR SARCOIDOSIS 
37 SA2 62/F - - - 
NIL 
RESPIR
ATORY 
NORMA
L - 
DD1,DD
2 DD4 -DO- TB/SAR 
SARCOI
DOSIS 
38 SAR3 45/F - - - 
NIL 
RESPIR
ATORY 
RES - DD1,DD2 DD4 -DO- T/SAR 
SARCOI
DOSIS 
39 SIL1 41/M + + CRAMIC 5YRS RES - DD2  SIL,SAR,LC,HP 
CVD,IPF
,SIL,SAR
,INF 
SILICOS
IS 
40 SIL2 54/M + + SILICA 7YRS RES - DD1,DD2 DD4 -DO- 
IPF,SIL,
SAR,HP,
INFECTI
ONS 
SILICOS
IS 
41 SIL3 49/M + - SILICA 12YRS RES -  DD4 SIL,PMF 
SIL,SAR
IPF,CVD
,INF 
SILICOS
IS-PMF 
42 SIL4 39/M + + SILICA 4YRS RES - DD1,DD2  _DO_  
SILICOS
IS+PMF 
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43 SIL5 51/M + + SILICA 10YRS RES - DD1,DD2  
T,SIL,TR
EATED 
LYMPH
OMA,HI
STOPLA
SMOSI 
SAR,NSI
P,HP,SIL
INF 
SILICOS
IS 
44 ABPA1 35/F - - - 12YRS OBS NIL DD1,DD2,DD3 DD7 
ABPA,C
YSTIC 
FIBROSI
S 
ABPA,C
EP,CHU
RG-
STRAUS
S 
ABPA 
45 ABPA2 46/F - - - 15YRS OBS NIL DD1,DD2,DD3 DD7 
ABOVE 
+AEP((?
UCUS 
IMPCTI
ON) 
ABPA,C
EP ABPA 
46 LC1 65/F - - CHEMO/RT 
15DAYS
(COUGH
) 
RES NIL DD1,DD2  
RP,LC,LI
P,PE 
CYTOL
OGY+M
ALIGNA
NT 
CELLS 
LC 
47 LC2 61/F - - CHEMO/RT 
20DAYS
(COUGH
) 
RES NIL DD1,DD2 DD4  
SAME 
AS 
ABOVE 
LC 
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48 ARDS1 60/F - - - 1WEEK - NIL DD1,DD2 DD4 
CXR-
ARDS,V
AP 
ARDS,D
AD,HP,I
NF 
ARDS 
49 ARDS2 44/M - - - 1WEEK -  DD1,DD2 DD4 
CXR-
ARDS,V
AP 
-DO- ARDS 
50 AB1 22/F - - 
DRUGS_
ANTIPS
YCHOTI
CS 
2YRS - NIL 
 
 
DD1,DD
2 
 
 
 
CHRONI
C 
ASPIRA
TION 
PNE,EN
DBRON
CHIAL 
TB,AB 
SPIRATI
ON 
PNEUM
ONIA,C
D,INFEC
TIONS 
 
 
ASPIRA
TION 
BRONC
HIOLITI
S 
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AAD 
(MEAN 
YEARS) 
MALE 
(%) 
DURATION 
MEAN YEARS 
DIAGNOSIS TCC AM LY NE EOS HIS 
           
           
    NC      0 
1 51.2 88.8 3.1 IPF 87 49 29 25 0 0 
2 53.2 82.3 14.3 CHP 95 50 39 10 0 0 
3 44.4 22.2 1.5 CVD 101 57 29 19 0 0 
4 44.0 0 - SAR 110 45 33 22 0 0 
5 46.8 100 - SIL 103 71 20 9 0 0 
6 52 50 - ARDS 340 38 25 37 0 0 
7 40.5 0 3 ELD 90 48 17 7 29 0 
8 63 0 45 DAYS LC 100 59 25 16 0 0 
9 20 0 2 AB 96 54 12 32 0 0 
10 49 100 180 DAYS PLCH 100 0 10 0 0 90 
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ABBREVIATIONS: 
 
IPF- idiopathic pulmonary fibrosis, S-smoking, A-alcohol intake, 
Exp-exposure, D.O.I- duration of illness, PFT-spirometry, RES-
restrictive, RHE-rheumatology diagnosis, RA-rheumatoid arthritis,SSc- 
systemic sclerosis, BAL1-bronchoalveolar lavage primary level dd, 
BAL2- bronchoalveolar lavage secondary level, CLI-clinical, AE-acute 
exacerbation, SAI- superadded infection, ALI-acute lung injury, BA- 
bronchial asthma, ELD- eosinophilic lung disease, INF-infection, ABPA-
allergic bronchopulmonary aspergillosis, UIP-usual interstitial 
pneumonia, FIB-NSIP- fibrotic NSIP, CLN- centrilobular nodule,SSc - 
systemic sclerosis, PMF-progressive massive fibrosis, SIL- silicosis, 
SAR-sarcoidosis, CHP-chronic hypersensitivity pneumonitis, AHP-acute 
hypersensitivity pneumonitis, GGO- ground glass opacities, LC-
lymphangitis carcinomatosis,AB-aspiration bronchiolitis 
 
 
 
 
73 
 
 
 
Age group No 
20-40 years 11 
41-60 years 29 
>60 years 10 
 
 
Out of 50 patients the above Graph shows the representation of age 
groups. 
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GENDER NO 
Female 20 
Male 30 
 
 
Out of 50 patients the above pie chart shows the gender distribution. 
 
 
 
 
 
 
Female
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Male
60%
Gender distribution
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SYMPTOMS NO 
Dyspnoea 36 
Cough 7 
Wheeze 2 
Nil 5 
 
 
 
 
Out of 50 patients studied the predominant  symptom was dyspnea. 
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Non smoker 36 
Smoker 14 
  
 
 
The above pie chart represents the distribution of smoking status of the 
patients studied. 
non smoker
72%
smoker
28%
Pattern of smoking
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PFT Number of patients 
Obstructive 8 
Restrictive 22 
Mixed 15 
Not done 2 
normal 3 
 
 
 
 Out of the 50 patients studied the predominant pulmonary function 
testing pattern was restriction as shown above.  
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HRCT PATTERN NO OF PATIENTS 
Proximal bronchiectasis 2 
Cystic 2 
Fibrosis 5 
Nodular 4 
Not done  2 
NSIP 10 
UIP 23 
PMF 2 
 
 
The above represents the distribution of the various HRCT patterns in the 
patients studied. 
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The distribution of the various ILDs are represented below 
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Among the 50 patients studied, the above graph represents the conditions 
showing total cell counts  (BAL) in relation to the normal control (NC). 
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The above graph represents the Alveolar Macrophages levels in various 
ILDs in relation to the normal control. 
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The above graph represents the BAL Lymphocyte variations in relation to 
the normal control values in different ILDs 
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The above graph shows neutrophil counts variations in relation to the 
normal control in various ILDs. 
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The above graph represents the mean age at Diagnosis of different ILDs 
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The above graph shows gender preponderance of different ILDs 
with silicosis being exclusive in males, IPF and CHP predominantly 
occurring in males. And sarcoidosis, CVD occurring more in females, in 
the population studied. 
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ABBREVIATIONS 
IPF  - Idiopathic Pulmonary fibrosis 
CHP  - Chronic hypersensitivity pneumonitis 
CVD  - Collagen Vascular Disease 
SAR  - Sarcoidosis  
SIL  - Silicosis 
ARDS - Adult respiratory distress syndrome 
ELD  - Eosinophilic Lung Disease 
RP  - Lymphangitis Carcinomatosis 
AB  - Aspiration Bronchiolitis 
PH  - Pulmonary Histiocytosis 
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Lymphangitis carcinomatosis was seen in the 6th decade, IPF and 
CHP in 5th decade, ELD, CVD, SAR, and SIL were noticed in the 4th 
decade of life. The average duration of the disease was 3.1 years, 14.1 
years and 1.5 years for IPF, CHP and CVD respectively.  
The lymphocytes in lung secretions was significantly high in IPF, 
CHP, CVD and SAR while the percentage of neutrophils were 
significantly high in all the sub groups of ILDs noted in the cohort on 
comparison to normal values. 
CHP- chronic hypersensitivity pneumonitis 
CVD- collagen vascular disease/ CTD-ILD 
SAR- sarcoidosis 
SIL- silicosis 
ELD- eosinophilic lung disease 
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IPF 
Eight patients were diagnosed with IPF based on clinical evaluation, 
pulmonary function test( restrictive pattern) and HRCT findings(sub 
pleural/basal reticulation and honey comb appearance). The cell cytology 
of BAL on seven IPF patients revealed a lymphocyte count range of 25% 
to 38%, and neutrophil count range 12% to 52%. For those with a 
neutrophil count range less than 50%, a diagnosis of idiopathic 
pulmonary fibrosis with bronchitis probably superadded infection was 
made. A diagnosis of IPF with  
Bronchitis and suppurative infection was made in one patient with 
a neutrophil count of above 50%. In patient 7 as the respiratory epithelial 
contamination was high and the analysis was forbidden due to sub 
optimal sample. 
CHP  
Out of 17 patients diagnosed with chronic hypersensitivity 
pneumonitis, patient CHP11 was not analysed due to suboptimal 
quality(PQ-poor quality)identified based on epithelial cells levels i.e. 
More than 5 percent. In the rest of the samples, the lymphocyte count 
range was 26% to 55% and the neutrophil count was in the range of 5% 
to 20%. Based on the cellular count, a diagnosis of acute exacerbation of 
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chronic hypersensitivity pneumonitis with bronchitis probably associated 
with superadded infection was made in all these patients. In addition to 
the above findings, patient 10 had 3% eosinophils, which redefined the 
diagnosis as acute exacerbation of chronic hypersensitivity pneumonitis 
with allergic bronchitis probably associated with superadded infection. 
CVD 
The lymphocyte range was 8% to 70% while the neutrophil count 
was in the range of 8% to 65% in nine patients. In patient CVD-1 as the 
lymphocyte count was 70% a diagnosis of acute exacerbation of 
interstitial lung disease with bronchitis probably associated with 
superadded infection was made. In patient CVD-2 with rheumatoid 
arthritis and a neutrophil count above 50% in the BAL cellular pattern, 
the diagnosis was refined as rheumatoid arthritis associated interstitial 
lung disease with bronchitis and suppurative infection. In the rest of the 
patients the diagnosis was refined as rheumatoid arthritis with interstitial 
lung disease with bronchitis probably due to with superadded infection. 
EOSINOPHILIC LUNG DISEASE: 
Apart from the routine lymphocyte and neutrophil count, 
eosinophil count of more than 25% was diagnostic of acute/chronic 
eosinophilic pneumonia and ABPA. 
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PULMONARY HISTOCYTOSIS:  
Predominance of histocytosis BAL fluid was able to narrow down 
this diagnosis. sarcoidosis:In three patients with sarcoidosis, the 
lymphocyte and neutrophil count range was 28% to 32% and 10% to 45% 
respectively. Based on BAL finding the previous diagnosis was refined as 
sarcoidosis induced interstitial lung disease with bronchitis probably 
associated with superadded infection. 
 
ARDS AND ASPIRATION BRONCHIOLITIS 
These diseases were diagnosed based on clinical history and 
examination and the role of BAL in defining the diagnosis was limited. 
  Lymphangitis carcinomatosa: BAL cytology yielded the diagnosis 
and made a biopsy unnecessary, in both the cases. 
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Overall, BAL findings were able to clinch the diagnosis in 
eosinophilic pneumonia, lymphangitis carcinomatosis and pulmonary 
histocytosis, while it refined the diagnosis of IPF and CHP.BAL helped 
in establishing infection as the cause of acute exacerbation in IPF,and in 
other ILDs. On the other hand, the role of BAL findings in sarcoidosis 
and silicosis was limited as HRCT had precisely help to diagnose the 
disease based on the image pattern. BAL had no role to play in the 
diagnosis of ARDS and aspiration bronchiolitis as the diagnosis is more 
on clinical history and evaluation. 
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STATISTICAL SIGNIFICANCE:  
 
  Statistically significant increase in the different cell counts were 
obtained for the following ILDs after comparison with normal cell 
counts; ARDS: alveolar macrophages(p=0.018), CHP: 
neutrophils(p=0.01), ELD: mast cells(p=0.000). A statistically significant 
decrease in the lymphocytes was noticed in ARDS(p=0.001) 
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DISCUSSION  
Usefulness of the clinical diagnostic test is graded based on its 
sensitivity, specificity, invasiveness, reproducibility and its contribution 
to the diagnosis of the disease. Based on these factors, new diagnostic 
tests for disease are invented and the old test wane of with time. 
Interestingly, as the pathogenesis of disease unwinds with time there may 
be need of multiple clinical tests to make precise diagnosis and to 
improve the management strategy. Under these situations, it may be 
difficult to conceive that an old test for a particular disease that has been 
used in the past may have new potential uses in modern medicine. 
Bronchoalveolar lavage(BAL) is now widely accepted as a safe 
procedure to sample alveolar secretions for studying cellular and acellular 
components for diagnostic purpose 106-111 . Bronchoscopy and BAL was 
once thought to hold a great scope in diagnosing and managing ILD. 
With time it came to understand, that though BAL immune cell features 
often had characteristics that were highly consistent with several forms of 
ILD, BAL cell profiles or soluble components could not reliably make a 
definite diagnosis in several forms of ILD if used as a standalone test of 
diagnosis. The evaluation of interstitial lung disease based on BAL 
findings was typically nonspecific, being consistent with or suggestive of 
a given condition, rather than pathognomonic, BAL data were subject to 
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considerable variability, and the potential number diseases are much more 
than the number of safely discernible cellular patterns. This, only in rare 
instances, the data lead to a unique conclusion; in the majority of cases, 
BAL cell differentials are only able to render some diagnoses more likely 
and to exclude others with some probability. This uncertainty, in 
combination with differences in clinical setting and experience, resulted 
in different opinions about the diagnostic value of BAL among clinicians. 
In early 1990s, HRCT came into widespread clinical use. As HRCT 
imaging patterns were consistent with specific forms of ILD such as IPF 
or sarcoidosis, the likelihood of making a diagnosis was high. Despite the 
acceptance of obtaining HRCT scan during the initial stages of patients 
with ILD, many patients with new onset ILD may not have the 
characteristic patterns that allow a diagnosis to be made with a high level 
of confidence by HRCT imaging alone. However, when clinical 
informations and HRCT findings were combined with BAL fluid 
analysis, confident diagnosis may emerge that obviate the need for 
surgical lung biopsy. Although the BAL cell pattern can provide useful 
information of the specific ILD diagnosis, this would be possible only if 
the bronchoscopist uses the appropriate technique to obtain the fluid, and 
the differential cell count is performed according to good clinical 
laboratory practice by personnel with adequate experience BAL 
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cytological analysis and interpreted by an expert familiar with the diverse 
spectrum of specific forms of ILD114,115. With this in mind the present 
study utilized the recommendations and guidelines of ATS concerning 
the use of BAL in the diagnosis and management of patients with 
suspected ILD. Based on the cellular pattern obtained we were able to fit 
the differential diagnosis of 47 patients within the classification provided 
by ATS. We were also able to find inappropriate BAL procedure in rest 
of the three patients. Later we made diagnosis of different ILDs based on 
clinical examination, HRCT findings and BAL cell pattern separately. 
And then with all the three modes of assessment. When a clinical 
diagnosis was combined with HRCT the differential diagnosis was 
narrowed down to minimum of two diseases. Considering BAL cellular 
pattern along with clinical examination and HRCT findings not only 
narrowed the type of ILD but also enhanced the diagnosis for better 
management strategy. The enhancement in the diagnosis included 
stability of the disease, acute or chronic nature of the disease and 
probable cause for acute exacerbation. This leaves the physician to take 
an appropriate decision to treat the cause of acute exacerbation along with 
the primary aetiology or to treat the primary cause alone. Thus, this 
multiple assessment strategy was able to treat patients appropriately with 
much more precision and accuracy. 
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In patient1 an IPF suspected patient HRCT had provided four 
differential diagnosis of IPF, CHP, asbestosis, sarcoidosis and CVD 
based on honeycoomb appearance. The clinical findings and BAL 
analysis suggested four differential diagnosis namely IPF, NSIP, acute 
lung disease and suppurative infection. Combining clinical, HRCT and 
BAL findings, the diagnosis was refined as acute exacerbation of 
idiopathic pulmonary fibrosis with bronchitis and probably associated 
with superadded infection. This had helped the clinician to treat the 
infection to control the acute episode. In patient 8, HRCT listed the 
differential diagnosis similar to that of patient 1 based on cystic changes 
honey comb appearance, but BAL clearly demonstrated predominance of 
histocytes in the lung secretion to narrow down the diagnosis as 
pulmonary histocytosis. This changed the modality of treatment in this 
patient. 
In patient 10, with a clinical diagnosis as ILD, HRCT revealed 
bilateral upper lobe fibrosis with traction bronchiectasis. Adding BAL 
input redefined the diagnosis as sub acute exacerbation of CHP associated 
with non infectious bronchitis based on the lymphocyte and neutrophil 
counts. On the other hand, patient 12 had a neutrophil count more than 
50% in the cellular pattern that gave a diagnosis of acute exacerbation of 
CHP with bronchitis and suppurative infection. In eosinophilic 
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pneumonitis BAL played a very important role in assisting clinical and 
HRCT findings to clinch the diagnosis. In some of the ILDs such as the 
sarcoidosis, silicosis, ILD associated with collagen vascular diseases 
HRCT stands as the important test along with clinical examination in 
determining the diagnosis. In all these diseases BAL was helpful to 
predict the acute/ sub acute or chronic nature of the disease and the 
association of infection. Whereas in ARDS the clinical criteria along with 
x ray chest was adequate to make a diagnosis. 
Thus the present study was able to demonstrate that BAL done as 
per the guidelines of ATS may act as an important test along with clinical 
and HRCT findings for a proper diagnosis in some ILDs, while in others, 
HRCT was found to be very successful in predicting the diagnosis, BAL 
assist in predicting the acute/chronic nature of the disease and gives the 
hint on the superadded infection status that would help in proper 
management. Thus BAL may be a routine test in eligible ILD patients 
along with clinical evaluation and HRCT. 
98 
 
 
CONCLUSIONS 
 
 BAL cellular profile obviates the need for surgical lung biopsy in 
certain ILDs namely lymphangitis carcinomatosis, Eosinophilic 
lung diseases and Langerhans cell histiocytosis. 
 
 BAL cellular profile could be supportive of diagnosis in the 
presence of clinical and radiological features typical of a specific 
ILD 
 BAL plays an important role in establishing infection as the cause 
of an acute exacerbation of ILD. If infection is not established, 
guides the clinician to look for an alternate cause such as a 
thromboembolic event or a left heart failure  
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BAL cellular analysis has documented the presence of 
inflammatory cells in asymptomatic patients with HRCT evidence 
of early ILD, which could predict an exacerbation in the near 
future. 
 BAL is a relatively safe procedure, and maybe a routine test in 
ILD(in the absence of contraindications to bronchoscopy), along 
with clinical evaluation and HRCT  
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STUDY LIMITATIONS 
 
 Sample size was small 
 This study did not include all types of ILDs, namely 
Cryptogenic Organising Pneumonia,  Acute Interstitial 
Pneumonias, Drug induced ILDs to name a few.  
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2. OBJECTIVE (S) / AIM 
 
Primary Objective 
 
To optimize the Brochoalveolar Lavage (BAL) procedure as per the 
recommendations put forth by the American Thoracic Society for the cellular analysis 
of interstitial lung diseases. 
 
Secondary Objectives 
 
 Optimization of the BAL procedure as per the recommendations of the 
American Thoracic Society 
 BAL cellular analysis association with clinical characteristics of different 
interstitial lung diseases and their radiological/pathological findings. 
 
 
3. INTRODUCTION 
 
Bilateral parenchymal infiltration of lung tissue is called interstitial lung 
disease (ILD). It can present as an acute or chronic condition with variable degree of 
inflammation and fibrosis. The condition is immune mediated where infection and 
neoplasm do not play a role in the etiology of the disease. ILDs are generally 
characterized clinically by exertional dyspnea, bilateral pulmonary infiltrates on 
thoracic imaging, abnormal pulmonary physiology, and abnormal gas transfer. They 
are characterized pathologically by an accumulation of inflammatory and immune 
effector cells that is often accompanied by abnormal extracellular matrix in the distal 
airways, alveolar walls, and interstitium.  
 
 
 
 
Chronic ILDs usually evolve over months to years and include disorders of 
both known and unknown causes. Among the ILDs with known causes or associations 
are the pneumoconioses, ILD associated with connective tissue disease (CTD-ILD), 
and hypersensitivity pneumonitis (HP). Among the ILDs of unknown cause are 
sarcoidosis and idiopathic interstitial pneumonias (IIP). Idiopathic interstitial 
pneumonia (IIP) includes idiopathic pulmonary fibrosis (IPF), nonspecific interstitial 
pneumonia (NSIP), desquamative interstitial pneumonia (DIP), respiratory 
bronchiolitis with interstitial lung disease (RBILD), acute interstitial pneumonia 
(AIP), cryptogenic organizing pneumonia (COP), and lymphoid interstitial pneumonia 
(LIP). 
 
Bronchoalveolar lavage has been used evaluate patients with suspectedILD to 
identify the specific type of ILD. Advent of high resolution computed tomography 
(HCRT) has reduced the clinical utility of BAL.  HRCT can noninvasively identify 
specific imaging patterns that may be virtually diagnostic or strongly support certain 
forms of ILD. This has greatly improved the clinician’s ability over the past decade to 
narrow the differential diagnosis. As a result, a likely diagnosis is determined in the 
majority of cases (1–3). The widespread use of HRCT to evaluate patients with ILD 
has reduced the need for invasive diagnostic procedures, although sampling is still 
performed to confirm or secure an accurate diagnosis. Diagnostic sampling is also 
performed when there is ongoing clinical suspicion of ILD despite a normal HRCT 
(i.e., occasionally patients whose HRCT was interpreted as normal have evidence of 
ILD on BAL or lung biopsy). Following the initial clinical andradiographic evaluation 
of patients presenting with suspected ILD, BAL cellular analysis may be a useful 
adjunct in the diagnostic evaluation of individuals who lack a confident usual 
 
 
 
interstitial pneumonia (UIP) pattern on high-resolution computed tomography 
(HRCT) imaging of the thorax.  
 
BAL is one sampling technique. It samples the cellular and acellular 
components of distal bronchioles and gas exchange units. BAL analysis is seldom 
diagnostic by itself, but BAL cell pattern results may support a diagnosis and/or 
narrow the differential diagnosis when considered in the context of the medical 
history (e.g., occupational and environmental exposures, drug ingestion, prior 
radiation therapy), physical examination (e.g., extrapulmonaryabnormalities), and 
radiologic findings (e.g., HRCT findings). The usefulness of BAL cell profiles is the 
subject of ongoing debate and controversy because its findings are hampered by poor 
sensitivity and specificity (4). In addition, a normal BAL differential cell profile does 
not exclude the presence of microscopic abnormalities in lung tissue. The clinical 
utility of BAL in identifying the cause of ILD is proven, provided the technique is 
performed correctly, BAL fluid be handled and processed properly.  Recently, the 
American Thoracic Society (ATS) clinical practice guideline provides a 
comprehensive, conceptually balanced, and evidence-based perspective on the clinical 
utility of BAL cellular analysis for the evaluation of suspected ILD. These guidelines 
will increase the utility of BAL in the diagnostic evaluation of ILD and promote the 
use of BAL in clinical of ILD so that future guidelines may be based upon higher 
quality evidence. 
The present work would utilize the recommendations put forth by the ATS to 
optimize the BAL procedure and associate the finding across different clinical entities 
of ILD including HRCT. In addition, the study would also associate BAL findings 
with lung tissues procured through transbronchial biopsy in subset of patients for 
 
 
 
whom biopsy is warranted (5).This may facilitate future clinical studies in patients 
with suspected ILD, which investigate potential biomarkers in BAL that may predict 
prognosis and response to therapeutic interventions for ILD. 
 
4.METHODOLOGY (MATERIALS & METHODS) 
 
 
Subject Selection 
 
Seventy five ILD patients will be enrolled for the study based onclinical and 
radiological evaluation after institutional ethics committee approval. 15 ml of 
peripheral blood would be collected from the patients after obtaining informed 
consent for the study. The blood samples will be utilized for routine blood 
investigations, disease specific investigations and for genetic analysis. 
 
Inclusion Criteria 
 
 ILD patients diagnosed based on clinical and HRCT findings 
 
 Acute and chronic ILDs in immunocompetentpatients. 
 
 ILD patients tolerable to the procedure. 
 
 Patients above 18 years of age. 
 
 Patients with ability and voluntarily signs the informed consent. 
 
 
Exclusion Criteria 
 
 ILD patients without HCRT diagnosis 
 
 ILD patient with immunodeficiency 
 
 ILDs associated with infection or neoplasm 
 
 ILD patients with bleeding tendency. 
 
 Pediatric patients 
 
 Pregnant women 
 
 
 
 
 
Screening Procedures / Visits: 
 
1. BAL is performed with the fiberoptic bronchoscope in a wedge position within the 
selected bronchopulmonary segment. The total instilled volume of normal saline 
should be no less than 100 ml and should not exceed 300 ml. Three to five 
sequentially instilled aliquots are generally withdrawn after each aliquot instillation 
(6). 
2. For optimal sampling of distal airspaces, the total volume (pooled aliquots) 
retrieved should be greater than or equal to 30% of the total instilled volume. A total 
volume of retrieved fluid less than 30% may provide a misleading cell differential, 
especially if total retrieved volume is less than 10% of total instilled volume. If less 
than 5% of each instilled aliquot volume is recovered during the procedure due to 
retention of most of the fluid in the lavaged segment, the procedure should be aborted 
to avoid increased risk of tissue disruption and/or inflammatory mediator release due 
to overdistention of the lavaged segment. 
3. A minimal volume of 5 ml of a pooled BAL sample is needed for BAL cellular 
analysis. The optimal volume is 10 to 20 ml. It is acceptable to pool all aliquots of the 
retrieved BAL fluid for routine analyses (including the first retrieved aliquot). 
4. BAL cell differential counts with greater than 15% lymphocytes, greater than 3% 
neutrophils, greater than 1% eosinophils, and greater than 0.5% mast cells represent a 
lymphocytic cellular pattern, neutrophilic cellular pattern, eosinophilic cellular 
pattern, and mastocytosis, respectively. Each has diagnostic implications. 
5. A predominance of macrophages containing smokingrelated inclusions with no or 
minor increases in other cell types is compatible with smoking-related ILD such as 
desquamative interstitial pneumonia (DIP), respiratory bronchiolitis interstitial lung 
disease (RBILD), and 
Langerhans cell histiocytosis. 
 
I. PRE-PROCEDURE PREPARATION 
 
Patients with suspected ILD for whom the clinician is considering BAL should 
undergo routine clinical evaluation before the procedure. This evaluation, which 
 
 
 
includes inquiry and appropriate testing for bleeding tendencies, is intended to 
minimize the likelihood of procedure-related complications by identifying potential 
risk factors that can be corrected or mitigated in advance. Once it is confirmed that the 
patient is a suitable candidate forBAL, the procedure may be scheduled.  
 
Recommendation 1. 
 
For patients with suspected ILD in whomit has been decided that a BAL can 
be tolerated and will beperformed, we suggest that the BAL target site will be chosen 
onthe basis of an HRCT performed before the procedure, ratherthan choosing a 
traditional BAL site (i.e., the right middle lobe or lingula). HRCT can be useful for 
identifying target areas of the lungthat are most likely to provide diagnostic specimens 
when samplingvia BAL. Generally, areas of alveolar ground glass opacity, more 
prominent nodular profusion, or fine reticulation are likely to provide optimal targets. 
Target areas as well as characteristics of parenchymal abnormalities may change with 
time and, therefore, the HRCT should not be performed too far in advance of the BAL 
procedure. Although there are no controlled clinical trials that have compared whether 
BAL sites identified by HRCT yield more useful information than traditional BAL 
sites (i.e., easily accessible sites that provide a good volume of return such as the right 
middle lobe or lingula), some reports suggest that HRCT may be useful for choosing a 
site of lavage. 
 
II. THE BAL PROCEDURE 
 
During standard flexible bronchoscopy, the bronchoscope is placed in a wedge 
position within the selected bronchopulmonarysegment. Normal saline (at room 
temperature) is instilledthrough the bronchoscope, with a total volume that is between 
100 and 300 ml and divided into three to five aliquots. After the instillation of each 
aliquot, instilled saline is generally retrieved using a negative suction pressure less 
than 100 mm Hg. The negative suction pressure should be adjusted to avoid visible 
airway collapse. The minimal total volume retrieved should be greaterthan or equal to 
5% of the instilled volume (optimal samplingretrieves >30%). If less than 5% of each 
instilled aliquot volume is recovered during the procedure due to retention of most of 
 
 
 
the fluid in the lung, the procedure should be aborted to avoid increased risk to the 
patient. A minimal volume of 5 ml of a pooled BAL sample is needed for BAL 
cellular analysis (the optimal volume is 10–20 ml); it is acceptable to pool all aliquots 
of the retrieved BAL fluid for routine analyses. Occasionally, the gross appearance of 
the BAL fluid will provide diagnostic clues. For example, grossly bloody BAL fluid 
that returns with increasing intensity in sequential aliquots indicates acute diffuse 
alveolar hemorrhage, while grossly cloudy (i.e., milky or light brown-beige color) 
BAL fluid that returns with flocculent material that settles by gravity to the bottom of 
the container within 15 to 20 minutes of fluid retrieval is highly suggestive of 
pulmonary alveolar proteinosis (PAP). 
 
III. HANDLING OF THE BAL FLUID 
 
The BAL fluid should be collected in containers that do not promote cell 
adherence to container surfaces (e.g., silicone coated glass or polypropylene or other 
plastics that are designed for suspension tissue culture). Its method of transport then 
depends upon how long it is anticipated that it will take to reach the analytical 
laboratory. The specimens will be transported at 4°C (i.e., on ice). If a delivery time 
greater than1 hour is anticipated, then transport in the original lavage saline is 
discouraged. Instead, the cells should be centrifuged at a speed that maintains cellular 
integrity (e.g., 250–300 3 g for 10 min) and then resuspended in a nutrient-
supplemented medium (e.g., MEM125mM HEPES or RPMI 1640125mM HEPES) 
and stored at 4°C, where they may remain for up to 24 hours. If a centrifuge is not 
available, MEM or RPMI may be added to the pooled lavage sample with subsequent 
storage at 4°C for up to 12 hours, but the sample will be transported to the laboratory 
as soon as possible and a prolonged interval between BAL fluid retrieval and 
laboratory processing is discouraged. BAL fluid will not be frozen or transported with 
dry ice. 
 
IV. PROCESSING 
 
Prompt processing of the BAL fluid or cell suspension once it reaches the 
laboratory provides optimal results. Labware will be used that does not promote cell 
 
 
 
adherence to container surfaces. Specimens with gross mucus can be strained through 
loose gauze, or small amounts of mucus can be dissolved with dithiothreitol, if 
necessary. The specimen will then be centrifuged at an appropriate speed, 
resuspended, and analyzed. BAL fluid that is not going to be analyzed immediately 
will be centrifuged, the cell pellet resuspended in a nutrient supplemented medium, 
and then refrigerated at 48C for up to 24 hours. Cells that were already suspended in a 
nutrient supplemented medium due to delayed transport can simply be refrigerated at 
4°C. Specimens obtained more than 24 hours before are not suitable for analysis. 
 
 
 
V. BAL CELLULAR ANALYSIS IN THE DIAGNOSIS OF SPECIFIC ILD 
 
A variety of diagnostic studies may be performed on BAL fluid. In patients 
with suspected ILD, typical diagnostic studies are a differential cell count, 
microbiological studies (to screen for mycobacterial and fungal disease), and 
cytopathology. 
 
Recommendation 2. 
 
For patients with suspected ILD who undergo BAL, a differential cell count be 
performed on the BAL fluid. This includes lymphocyte, neutrophil, eosinophil, and 
mast cell counts. The remaining sample may be used for microbiological, virological, 
and/or malignant cell cytology laboratory testing, if clinically indicated. The reason 
for routine cellular analysis whenever BAL is performed in a patient with suspected 
ILD is that identification orexclusion of a predominantly inflammatory cellular 
pattern (increased lymphocytes, eosinophils, and/or neutrophils) maysupport a 
specific type of ILD or help narrow the differential diagnosis, when considered in the 
context of the clinical and radiological findings. The notion that a prominence of 
specific nucleated inflammatory or immune cells in the BAL correlates with an 
increased likelihood of certain types of ILD is supported by numerous accuracy 
studies that are limited by risk of bias. These include pronounced BAL eosinophilia in 
eosinophilic pneumonia (7, 8) or drug reactions (9–11), and BAL lymphocytosis in 
 
 
 
sarcoidosis (12–15), hypersensitivity pneumonitis (16–18), pneumotoxic drug 
reactions (19, 20), or cellular NSIP (21, 22).  
 
 
Follow up Procedures / Visits: 
 
The patient will be observed for 48 hours for post procedure bleed at the in-
patient ward before discharged with care. 
 
Assessments of Parameters 
 
TECHNIQUE OF BAL CELL ANALYSIS 
 
The cellular analysis will be performed within 1 hour if the BAL fluid is in 
nutrient-poor media (e.g., saline) or within 2 to 3 hours for optimal results if the BAL 
fluid is in a nutrient-supplementedmedium. The total cell count (nucleated immune 
cells) is usually obtained via a hemocytometer, and cell viability is determined by 
Trypan blue exclusion. Differential cell counts will be performed via 
cytocentrifugation with staining (Wright-Giemsa or May-Grunwald-Giemsa) and 
enumeration of at least 400 cells. The presence and relative numbers of erythrocytes 
and epithelial cells should be noted. The presence of squamous epithelial cells 
suggests that BAL fluid is contaminated with upper airway secretions, and the 
presence of large numbers of bronchial epithelial cells suggests that the BAL may not 
have adequately sampled distal airspaces. Excess BAL fluid will be stained and 
cultured for mycobacteria and fungi in the microbiology laboratory, as well as 
screened for neoplastic cells. These are important additional tests to consider because 
infections and diffuse neoplasms can masquerade as ILD or coexist with ILD. 
 
INTERPRETATION OF BALL DIFFERENTIAL COUNTS 
 
The ranges of differential cell counts that are considered normal and abnormal 
derive from several sources. Numerous investigators have published BAL immune 
cell profiles from cohorts of clinically normal volunteer subjects recruited in single-
center studies (22–28) and these reports have been used to define normal and 
abnormal differential cell counts. In addition, the multi-center BAL Cooperative 
Study (22) reported the differential cell counts in the BAL of normal subjects 
 
 
 
(including smokers or ex-smokers) compared with patients with ILD. An increased 
number of nucleated immune cells and abnormal proportions of immune cell types 
may suggest or support specific types of ILD in the absence of an infection. A mixed 
cellular pattern can be observed with any ILD; when mixed cellular patterns are 
observed, the dominant cell type may be the most consistent with a specific ILD 
diagnosis. A BAL fluid cell differential count with greater than 15% lymphocytes, 
greater than 3% neutrophils, greater than 1% eosinophils, or greater than 0.5% mast 
cells indicates BAL lymphocytosis (i.e., a lymphocytic cellular pattern), BAL 
neutrophilia (i.e., a neutrophilic cellular pattern), BAL eosinophilia (i.e., an 
eosinophilic cellular pattern), or BAL mastocytosis, respectively. A lymphocyte 
differential count greater than or equal to 25% suggests granulomatous lung disease 
(e.g., sarcoidosis, HP,  NSIP, chronic beryllium disease, drug reaction, LIP, COP, or 
lymphoma), while a lymphocyte differential count greater than 50% is particularly 
suggestive of HP or cellular NSIP. An eosinophil differential count greater than or 
equal to 25% is virtually diagnostic of eosinophilic lung disease in the appropriate 
clinical setting. A neutrophil differential count greater than or equal to 50% strongly 
supports acute lung injury, aspiration pneumonia, or suppurative infection. Finally, a 
mast cell differential count greater than 1% combined with a lymphocyte differential 
count greater than 50% and a neutrophil count greater than 3% is suggestive of HP. A 
predominance of macrophages containing smoking-related inclusions with no or 
minor increases in other cell types is compatible with smoking-related ILD, such as 
DIP, RBILD, or pulmonary Langerhans cell histiocytosis (PLCH). Additional tests to 
identify and count Langerhans cells in the appropriate clinical setting may be useful in 
narrowing the differential diagnosis. A predominance of hemosiderin-laden 
macrophages is suggestive of chronic or occult alveolar hemorrhage syndromes 
resulting in pulmonary hemosiderosis or diffuse alveolar damage.  
 
Recommendation 3. 
 
For patients with suspected ILD in whom BAL is performed, the lymphocyte 
subset analysis NOT be a routine component of BAL cellular analysis. The 
lymphocyte subset analysis (by cytometry or immunocytochemistry) will not be 
performed routinely, but rather would be performed if a lymphocytic disease is 
 
 
 
suspected or the initial BAL cellular findings identify a lymphocytosis. This 
suggestion is based upon the committee’sclinical experience that lymphocyte subset 
analysis is rarely helpful and potentially misleading in the absence of a clinically 
suspected lymphocytic disease or a lymphocytosis. Many investigators have 
characterized lymphocyte subsets on the basis of T helper (CD41) versus T suppressor 
(CD81) phenotypes, and have found correlations of the CD41/CD81T lymphocyte 
ratio with specific disease processes such as sarcoidosisand hypersensitivity 
pneumonitis (16,17,29,30). However, subsequent investigations have found that the 
CD41/CD81 ratio may not be significantly increased in a substantial number of 
patients with sarcoidosis (31,32) or significantly decreased in a substantial proportion 
of patients with hypersensitivity pneumonitis (33,34), and can change during the 
course of the disease process. In addition, the BAL CD41/CD81T lymphocyte ratio 
varies with age and may be significantly increased in normal subjects (35). These 
issues are discussed extensivelyin the portion of the online supplement that pertains to 
specific forms of ILD. However, in the case of sarcoidosis, the combination of BAL 
lymphocytosis combined with a considerablyincreased BAL CD41/CD81 lymphocyte 
ratio (e.g., >4) may increase the confidence of a diagnosis of sarcoidosis if other 
clinical features and imaging are consistent with this diagnosis, and lymphocyte 
subset determinations may be performed at the discretion of the pulmonologist if such 
analysis can be reliably performed in the clinical laboratory and is considered to be 
clinically useful. Finally, there are other tests that can be performed on BALfluid on a 
case-by-case basis and may be helpful in specific clinical circumstances. Analysis by 
a cytopathologist is indicated if there are isolated cells that are suspicious for 
malignancy. Periodic Acid Schiff staining or Oil Red O staining may be helpful if 
pulmonary alveolar proteinosis or aspiration is suspected, respectively. Hemosiderin 
staining may be performed if hemorrhage is suspected and/or the initial BAL raises 
the suspicion of hemosiderin-laden macrophages.  
 
 
 
 
5. RESULTS 
 
 
Statistical Analysis Plan 
 
Cellular analysis will be separately compared between different types of ILDs 
using the Mann–Whitney U test. Associations between phenotypic characteristics will 
be studied by Pearsons coefficient of correlation. All analyses will be performed with 
SPSS version 14.0 (SPSS Inc., Chicago, IL) and p<0.05 was considered significant. 
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